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活化蛋白激酶(c-Jun N-terminal kinase/stress activated protein kinase, JNK/SAPK)磷 
vi 
酸化作用（即活化作用）的影響，結果顯示CHL治療能降低JNK的磷酸化作用。活 

























Chlorophyllin (CHL) is a mixture of sodium copper salts of chlorophyll derivatives. 
CHL has been reported previously as an effective chemopreventive agent against 
hepatocellular carcinoma development and as a suppressing agent, which induces 
apoptosis in human colon cancer cells. Most importantly, no observable adverse effect of 
CHL has been reported. To further increase our knowledge on the anticancer property of 
CHL, the current study had examined the growth response of a number of cancer cell 
lines of different histotypes to CHL treatment using MTT assay; in which, the human 
breast carcinoma MCF-7 was found to be the most responsive one. Thus, the 
growth-inhibitory effect of CHL was further investigated on MCF-7 cells, which has not 
yet been reported by other researchers. 
Effect of CHL on the proliferation of MCF-7 cells was measured by 
chemiluminescent 5-bromo-2‘-deoxyuridine (BrdU) cell proliferation ELISA assay. The 
cancer cell proliferation at 72 h of incubations with doses 25 to 400 fig/ml of CHL was 
inhibited dose-dependently. The concentration of CHL with 50% inhibition on the cancer 
cell proliferation, i.e., IC50, was estimated to be 123.5 fig/ml. The cytostatic and cytotoxic 
effects were explained by the cell-cycle arrest and apoptosis induced by CHL. Results 
from the DNA-flow cytometry showed that the increase of G Q / G I cells was 
well-correlated with the depletion of Cyclin D1 expression, illustrated by the immunoblot 
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analysis, during the early phase of treatment, i.e., 24 h，with the IC50 of CHL. On the 
other hand, during the later phase of treatment, i.e., 48-96 h, G2/M arrest and apoptosis 
were observed. Mitogen-activated protein kinases (MAPKs) are a group of protein 
serine/threonine kinases activated in response to a variety of extracellular stimuli and 
mediate signal transduction from the cell surface to the nucleus for a variety of biological 
responses. To better understand the upstream signal transduction pathways causing the 
proliferation inhibition and apoptosis, effect of CHL on the phosphorylation and hence 
activation of c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK), a 
subfamily of MAPKs, was evaluated. CHL treatment reduced the phosphorylation of JNK. 
It is well known that active JNK translocates to the nucleus where it phosphorylates c-Jun; 
the phosphorylated c-Jim then induces expression of Cyclin Dl . It was further 
demonstrated in this study that the phosphorylation of c-Jun was reduced by the CHL 
treatment, suggesting the CHL-induced downregulation of Cyclin Dl might be caused by 
the inactivation of JNK. As reported by other researchers, basal JNK activity is also 
required for the survival of MCF-7 cells and inhibition of JNK causes G2/M arrest. 
Therefore, results from the previous and present studies suggest that the inactivation of 
JNK is at least partially responsible for the growth inhibition induced by CHL in the 
breast cancer cells. 
In addition to the cell-cycle arrest, this study also defined that the mitochondrial 
iii 
dysfunction induced by CHL plays a prominent role in the apoptosis in MCF-7 cells. CHL 
caused early dissipation of mitochondrial membrane potential at 24 h，which seemed to be 
independent of the apoptosis-modulatory Bcl-2, BC1-XL and Bad expressions. On the other 
hand, results from the immunoblot analysis illustrated that the levels of procaspase-9 and 
-6 were decreased after 72 h of incubation with the IC50 of CHL, suggesting that the 
caspases might be cleaved and thus become activated in the cell death process. 
Applications of the caspase-9 and caspase-6 inhibitors further confirmed the roles of the 
caspases in the CHL-induced apoptosis. However, application of the general caspase 
inhibitor failed to completely retard the apoptosis, demonstrating that the cell death 
process might also be mediated by some caspase-independent events in addition. 
Collectively, the results indicate that the signaling cascades initiated by CHL are 
integrated at the level of mitochondrial dysfunction so that both the caspase-dependent 
and caspase-independent death pathways are triggered in the breast cancer cells. 
In search for the in vivo anticancer activity of CHL, the study of nude mice 
transplanted with MCF-7 solid tumor and administered with CHL at dosage of 12.5 to 50 
mg/kg for 10 consecutive days showed that the tumor was regressed dose-dependently. 
The preliminary results from the immunoblot analysis also suggest that the retardation of 
the growth was at least associated with the depletions of Cyclin D1 and Bcl-2 
expressions. 
x 
In conclusion, the anticancer activity ofCHL on the human breast carcinoma MCF-7 
cells is mediated by both its antiproliferative and cytotoxic activities, via modulating the 
regulatory proteins in those processes. The results from this study provide the preliminary 
insights and support future research together with development of CHL as a novel 
anticancer agent. 
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Chapter 1 General Introduction 
1.1 An Overview on Cancer 
The maintenance of normal cell function and tissue homeostasis is dependent on the 
precise regulation of multiple signaling pathways that control cellular decisions to either 
proliferate, differentiate, arrest cell growth, or initiate programmed cell death (apoptosis). 
A new group of cells arises when clones of mutated cells escape this balance and 
proliferate inappropriately without compensatory apoptosis (Sears and Nevins，2002). 
This new group of cells forms a tumor or neoplasm, which can be classified as benign or 
malignant based on their likelihood of spreading. Benign tumors do not spread as they are 
usually encapsulated to form nodules of neoplastic tissue. In contrast, malignant tumors, 
which are usually referred to as cancers, give rise to pioneer cells that move out, invade 
adjacent tissues, and hence travel to distant sites where they may succeed in founding 
new colonies. These distant settlements of tumor cells are called metastases，which are the 
cause of 90% of human cancer deaths (Hanahan and Weinberg, 2000; Becker et al., 
2003). 
Tumors may arise from differentiated cells or from mitotically active stem cell 
populations. Stem cells are relatively undifferentiated, actively dividing cells from which 
some more highly differentiated cells originate. Cancers of a stem cell may be designated 
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by the suffix -owa, for example, neuroblastoma for a tumor of neuroblastic origin and 
fibroma for a tumor of fibroblastic origin. Another important element in tumor 
categorization is the tissue class of origin, in which carcinoma and sarcoma represent 
tumors derived from an epithelial tissue and a connective tissue, respectively. The 
hematopoietic system includes stem cell populations that grow and divide throughout life. 
All these populations are subject to neoplasia, for instance, lymphomas are tumors of the 
lymphocytic lineage, leukemias and myelomas are tumors of the leukocytic system 
(granulocytes, eosinophils, and basophils), and erythroblastomas are tumors of the 
erythroblastic (red blood cell) lineage (Becker et cd., 2003). 
Tumor development consists of several separate, but closely linked, stages including 
tumor initiation, promotion and progression. Initiation is considered to be a rapid and 
irreversible process, which includes the initial uptake of or exposure to a carcinogenic 
agent, its distribution and transport to organs and tissues where metabolic activation and 
detoxification can occur. The covalent interaction of reactive species with target-cell DNA 
leads ultimately to genotoxic damage. In contrast to initiation, tumor promotion is a 
relatively lengthy and reversible process in which actively proliferating preneoplastic 
cells accumulate. Progression, the final stage of neoplastic transformation, involves the 
growth of a tumor with invasive and metastatic potential (Surh, 2003). The development 
of a malignant tumor is a multistep process characterized by a progression of genetic 
2 
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alternations that make the cells increasingly less responsive to the body's normal 
regulatory machinery and better able to invade normal tissues (Crighton and Ryan, 2004). 
Functionally, cancer genes taken part in this process may belong to either oncogenes or 
tumor suppressor genes. Oncogenes are usually derived from normal cellular counterparts, 
the proto-oncogenes, which in their non-mutated form function as essential components 
of intracellular signaling pathways. They comprise ligands, receptors, molecular switches, 
cytoplasmic signal transducers and transcription factors. Functional heterogeneity is also 
seen among proteins with tumor suppressor activities, which include ligands, 
phosphatases, acetylases, and transcription factors. Mutations eliminate the negative 
impact on growth and survival and thereby contribute to tumor formation (Hanahan and 
Weinberg, 2000). Taken together, these genes involved in carcinogenesis constitute a 
specific subset of the genome whose products are involved in such activities as the 
progression of a cell through the cell cycle, adhesion of a cell to its neighbors, apoptosis, 
and the repair of DNA damage (Karp, 2003). In this sense, restoration of any genetic 
alternations back to their normal status by various different means, e.g. induced 
differentiation on pluripotent cancer cells, represent important clues to re-transform the 
cancer cells back to normal (Anderson et al.’ 1995; Aziz et al, 2003; Kim and Freeman, 
2003). 
Conventional therapeutic and surgical approaches have not been able to control the 
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incidence of most of the cancer types. Thus, there is an urgent need to develop 
mechanism-based approaches for the management of cancer, that means to develop 
strategies which can eliminate only the damaged (pre-malignant) or malignant cells 
without harming the normal ones. Chemoprevention via non-toxic agents could be such 
an approach to combat cancers (Mukhtar and Ahmad, 1999; Aziz et al., 2003). Recently, 
scientists have attached great importance on the effects of dietary phytochemicals on 
cancer chemoprevention. Chemopreventive phytochemicals are non-nutritive components 
in the plant-based diet, which can block initiation or reverse the promotion stage of 
multistep carcinogenesis. They can also halt or retard the progression of precancerous 
cells into malignant ones (Wattenberg, 1985). There is a general consensus among 
epidermiologists that some ingredients in the diet, such as animal fat and alcohol, can 
increase the risk of developing cancer, whereas certain compounds found in fruit and 
vegetables can reduce that risk (Karp, 2003). Vegetables and fruit are excellent sources of 
cancer-preventive substances. The National Cancer Institute (NCI) of the United States 
has identified about 35 plant-based foods that process cancer-preventive properties. These 
include garlic，soybeans, ginger, onion, turmeric, tomatoes and cruciferous vegetables (for 
example, broccoli, cabbage, cauliflower and Brussels sprouts). Currently, the NCI has 
made chemoprevention research a top priority; it has sponsored more than 65 Phase I， 
Phase II and Phase III chemoprevention trials and more than 400 potential agents are 
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under investigations (Surh, 2003). 
In the present study, chlorophyllin (CHL) (Fig. 1.1), which aroused public attentions 
as chemopreventive phytochemical, was investigated. It was found in this study that the 
human breast carcinoma MCF-7 was most responsive to the exposure of CHL among the 
various cancer cell lines tested. The mechanistic actions of CHL for the growth-inhibitory 
effects on the breast cancer cells were then investigated. Breast cancer is one of the most 
common malignancies in women and is the leading cause of death worldwide for women 
between the ages 40 and 55 years (Baselga and Mendelson, 1994). This pathology is 
currently controlled by surgery and radiotherapy and is frequently supported by adjuvant 
chemo- or hormonotherapies (Bange et al., 2001). However, breast cancer is highly 
resistant to chemotherapy, and there is still no effective cure for patients with advanced 
stages of the disease, especially in cases of hormone-independent cancer (Bange et ai, 
2001; Chopin et al., 2004). Effective chemopreventive treatment for breast cancer would 
have an important impact on breast cancer morbidity and mortality. The epithelial breast 
cancer-derived MCF-7 cell line is one of the widely used cellular systems for breast 
cancer. Since this cell line is originally derived from infiltrating carcinoma, the 
commonest type of breast cancer in the world (Karami-Tehrani and Salami, 2003)， 
identifying agents and mechanisms of chemoprevention against MCF-7 cells is one of the 
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Fig. 1.1 Chemical Structure of Chlorophyllin 
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1.2 Biological Effects of Chlorophyllin 
Chlorophyllin is a semi-synthetic water-soluble salt obtained by alkaline hydrolysis 
of chlorophyll with replacement of the magnesium by copper and methyl and phytyl ester 
groups by sodium. CHL is marketed as an over-the-counter drug in doses up to 300 
mg/day for controlling body, fecal and urinary odor in geriatric and osteomy patients and 
as an accelerant in wound healing (Young and Beregi, 1980). CHL is also approved by 
Food and Drug Administration (FDA) as a food additive for "green" coloration (NNR 
food dye El41) (Hendry, 1996). Recent studies have shown that CHL is an effective 
antimutagenic and antigenotoxic agent (Dashwood, 1997; Egner et al., 2001) and has 
been suggested as a cancer chemopreventive phytochemical with no observable adverse 
effect (Chemomorsky and Segelman, 1988). The known pharmacological properties of 
CHL are then discussed. 
1.2.1 CHL as Photosensitizer 
Previous studies suggested that CHL or other chlorophyll derivatives, which absorb 
the wavelengths that best penetrate mammalian tissues while producing no substantial 
skin sensitivity, might be used in photodynamic therapy (PDT) (Roberts et cd., 1989; 
Spikes, 1990). The chlorophylls and their derivatives, as light-sensitive agent of 
photosensitizers, are selectively retained by the tumor cells. After surgical resection of the 
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main tumor, monochromatic light or ultrasonic excitation is used to destroy the residual 
tumor cells. The mechanistic actions involve absorption and transferring energy from 
photons to oxygen molecules by the light-excited photosensitizer molecules in an 
oxygen-rich environment; reactive oxygen species (ROS) are thus formed causing 
damages to proteins, lipids, nucleic acids and other cellular components in the cancer 
cells (Hajri et al” 1999). Among various chlorophylls and their derivatives that have been 
studied in this context, CHL has received particular attention as it is the water-soluble 
derivative of chlorophyll, and has been used in the treatment of various human aliments 
with no evidence of toxicity, skin sensitization, or other serious side effects 
(Chemomorsky and Segelman, 1988; Roberts et aL, 1989). 
1.2.2 CHL as Antioxidant 
CHL is beneficial to our bodies since it is an antioxidant and protects our cells 
against undesirable lipid peroxidation and membrane damage. Exposure to adverse 
pathophysiological states causes enhanced generation of the ROS resulting in oxidative 
stress. ROS are ubiquitous in our aerobic environment; however, their excess generation 
has been implicated in a number of diseases such as cancer, cardiovascular ailments, 
neural disorders, arthritis and diabetes, besides in the process of aging (Kunsch and 
Medford, 1999). Among the ROS, hydroxyl radical, peroxyl radical and singlet oxygen 
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are the major species that induce membrane damage in cellular systems leading to 
cytotoxicity and cell death (Paillous and Ferry-Forgues, 1994). In a previous study, using 
rat liver mitochondria as model system and various sources for the generation of ROS, 
CHL was demonstrated to possess membrane-protective properties against damage to 
lipid as well to protein both under in vitro and ex vivo conditions (Kamat et ai, 2000). 
1.2.3 CHL as Anticarcinogenic Agent 
One of the first studies to examine the inhibitory mechanisms of CHL on 
anticarcinogenic activities in vivo showed decreased activities of aminopyrine 
N-demethylase and aniline hydroxylase and a lower content of cytochrome P450 in liver 
microsomes of rats exposed to CHL by intraperitoneal (i.p.) injection (Imai et al.’ 1986). 
Cytochrome P450 enzyme is involved in the bioactivation of several environmental 
carcinogens, including aflatoxins in contaminated foods and polycyclic aromatic 
hydrocarbons (PAH) in cigarette smoke (Yun et al., 1995). It has been demonstrated that 
the P450 enzyme-bioactivated PAH produce DNA damage patterns that are similar to the 
tumor suppressor gene TP53 mutation patterns found in lung cancer tissues in smokers; 
exposure to one specific PAH, benzo[a]pyrene diol epoxide, induces guanine adducts at 
mutational hotspots within the TP53 gene，which is mutated in 60% of human lung cancer 
(Hecht, 2000). Inhibition of P450 enzyme activity by CHL may produce lesser amounts 
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of bioactivated mutagenic and genotoxic aflatoxins and PAH metabolites that cause lower 
level of damage to our DNA (Yun et al, 1995). 
Previous studies have also shown that CHL inhibits carcinogenesis in trout and rat 
by intercepting and forming tight complexes with different mutagenic and genotoxic 
agents, and thereby diminishes their bioavailability by shuttling them through fecal 
stream (Dashwood, 1992; Breinholt et al., 1999). One of the studies demonstrated that 
CHL dose-dependently inhibited the covalent binding of aflatoxin Bi (AFBi) to liver 
DNA when the carcinogen and inhibitor were co-administered in the diet (Dashwood et 
al., 1991). Protection was less effective when CHL was given in the diet and AFBi was 
administered by i.p. injection (Dashwood, 1997). The marked differences between the 
oral and i.p. effects of CHL suggested that there was a need for direct carcinogen/inhibitor 
interaction in the gut. 
In addition, similar conclusions were obtained from studies in which rats were given 
CHL and a cooked meat heterocyclic amine, 2-amino-3-methylimidazo [4,5quinoline 
(IQ). Co-injection of CHL and radiolabeled IQ directly into the ligated sections of the 
small intestine in situ inhibited the uptake of carcinogen from the gut. Rats given CHL 
and IQ simultaneously by single oral gavage had significantly reduced IQ-DNA binding 
levels in the liver (Dashwood, 1992). Total radioactivity in the liver, urine and bile was 
reduced in rats given CHL plus IQ compared with controls treated with IQ alone, and this 
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was accompanied by a concomitant increase in the amount of radiolabel eliminated in the 
feces. HPLC analysis of the excreted mutagens established that the CHL treatment 
increased the elimination of unmetabolized parent compound (Dashwood, 1992; 
Dashwood and Liew, 1992). Thus, the distribution pattern of radioactivity in vivo 
indicated that CHL interacted directly with IQ in the gut, leading to the reduced 
carcinogen uptake, distribution and metabolism. 
Residents at Qidong, People's Republic of China, are at high risk of development of 
liver cancer, in part from consumption of foods contaminated with aflatoxins. A 
randomized, double-blind, placebo-controlled trial was carried out by recruiting 180 
healthy adults from Qidong who were then randomly assigned to ingest 100 mg of CHL 
or a placebo 3 times a day for 4 months. CHL consumption led to an overall 55% 
reduction in median urinary levels of aflatoxin-N^-guanine biomarker compared with 
those taking placebo (Egner et al., 2001). The in vivo absorption and bioavailability of 
copper chlorin 64 ethyl ester and copper chlorin 64 in sera of individuals participating in 
the CHL chemoprevention trail further postulated that the mechanism of the cancer 
prevention might lie in the actions of these two components in vivo in addition to 
preventing carcinogen absorption in the gut (Egner et al., 2000). These two chlorin 
compounds are thus important biomarkers for characterizing the anticarinogenic 
bioactivities of CHL. 
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Besides being reported as an effective blocker on carcinogenesis, CHL has also been 
shown to act directly upon the aberrant cells in vitro. Diaz et al (2003) examined the 
response of human colon cancer HCT116 cells to CHL and suggested for the first time 
that CHL might induce apoptosis in the colon cancer by interacting possibly with the 
death receptors in its plasma membrane, and thus triggering caspase-8/caspase-6 
activation and Bid truncation. 
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1.3 Regulation of Cell Cycle 
The study of cell cycle is not only important in basic cell biology, but also it has 
enormous practical implications in combating cancer, a disease that results from a 
breakdown in a cell's ability to regulate its own division (Karp, 2003). A eukaryotic cell 
has to progress orderly through a series of stages, termed Gi, S, G2 and M，before it can 
divide into daughter cells (Norbury and Nurse, 1992). The M (mitotic) phase, the process 
of cell division, is the most visually distinctive part of the cell cycle. It encompasses two 
overlapping processes, mitosis and cytokinesis. In mitosis, sister chromatids are aligned 
and then segregated into two daughter cells; in cytokinesis, the cytoplasm and its content 
partitioned into those cells. Between divisions, the cell is said to be in interphase, which is 
made up of the S phase (the period of DNA replication) and two "gap" phases, called Gi 
and G2. The cell continues to grow throughout interphase, a time of high metabolic 
activity (Norbury and Nurse, 1992; Nigg，1995). 
1.3.1 Cell-Cycle Checkpoints 
To ensure proper progression through the cell cycle, cells have developed a series 
of checkpoints that prevent them from entering into a new phase until they have 
successfully completed the previous one. At each checkpoint, conditions within the cell 
determine whether or not the cell will proceed to the next stage of the cycle (Hartwell and 
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Weinert, 1989). The first checkpoint occurs late during the Gi phase, which is called the 
restriction point (Pardee, 1974). During G\ phase, cells integrate mitogenic and growth 
inhibitory signals, which make the decision to proceed, pause，or exit the cell cycle. Cells 
that have successfully passed through the restriction point are committed to S phase, 
whereas those that have not passed this point can exit the cell cycle and enter a 
non-dividing, quiescent known as Go. In addition to the Gi checkpoint, two other cell 
cycle checkpoints have been well-characterized. At the G2 checkpoint, located at the 
boundary between G2 and M phase, proper completion of DNA synthesis is required 
before the cell can initiate mitosis. In certain cell types, the cell cycle can be indefinitely 
arrested at this point if cell division is not necessary; under such conditions, the cells enter 
a resting state analogous to Go. The third cell cycle checkpoint, the spindle assembly 
checkpoint, is at the junction between metaphase and anaphase. Before cells can pass 
through the spindle assembly checkpoint and begin anaphase, all the chromosomes must 
be properly attached to the spindle. If the two chromatids that make up each chromosome 
are not properly attached to opposite spindle poles, the cell cycle is temporarily arrested 
at this point. In the absence of such a control mechanism, there would be no guarantee 
that each of the newly forming daughter cells would receive a complete set of 
chromosomes (Johnson and Walker, 1999; Becker et al., 2003). 
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1.3.2 Cell-Cycle Regulatory Proteins 
Some of the molecules that control the early events of cell cycle have been 
extensively characterized. The central players are the cyclin-dependent kinases (Cdks), a 
group of serine/threonine kinases that form active heterodimeric complexes following 
binding to cyclins, their regulatory subimits, whose concentration rises and falls in a 
predictable pattern as the cell cycle progresses (Pines, 1995; Morgan, 1997). Different 
members of the Cdk family, in association with different cyclins, turn key switches 
throughout the cell cycle; other family members regulate transcription, differentiation, 
nutrient uptake and other functions. By controlling the level of Cdk activity, Cdk 
regulators can also control cell-cycle commitment. They include activators, mainly the 
cyclins, and inhibitors, generically known as Cdk inhibitors. Cdks are also regulated by 
phosphorylation on a threonine residue for proper catalytic activity (Nigg, 1995; Morgan, 
1997). 
Cyclin-Cdk complexes are regulated by phosphorylation and protein interaction 
events that tightly control the timing and extent of Cdk activation. The cell cycle activities 
during mid Gi are accomplished primarily by Cdk4 and Cdk6 associated with the D-type 
cyclins (Dl, D2 and D3). Among the substrates for these Cdks is an important regulatory 
protein called retinoblastoma (Rb) (Pines, 1995; Morgan, 1997; Sherr and Roberts, 1999). 
The phosphorylation of Rb leads to the transcription of a number of genes, including 
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those that code for cyclins E and A, Cdkl, and proteins involved in replication (Ohtani et 
al” 1995; Schulze et al, 1995). The Gi-S transition, which includes the initiation of 
replication, is driven by the activity of the cyclin E-Cdk2 and cyclin A-Cdk2 complexes 
(Sherr, 2000). The transition from G2 to M is driven by the activity of cyclin A-Cdkl and 
cyclin B-Cdkl complexes, which are thought to phosphorylate such diverse substrates as 
cytoskeletal proteins, histories, and proteins of the nuclear envelope. Destruction of 
cyclins A and B is a key factor in the activation of Cdkl and the transition of the cell from 
mitosis back into Gi (King et al.’ 1994; Arellano and Moreno, 1997). 
Given the complexity of the cell cycle and its control mechanisms，it is perhaps 
not surprising that malfunctions occasionally occur resulting in uncontrolled proliferation. 
Tumor suppressor genes such as RB and TP53 encode proteins that restrain cell growth 
and prevent cells from becoming malignant. The absence or inactivation of them can lead 
to cancer (Hurford et al., 1997; Levine, 1997). At the present time, approximately two 
dozen genes have been implicated as tumor suppressors in humans (Karp, 2003). Most of 
the proteins encoded by tumor-suppressor genes act as negative regulators of cell 
proliferation, which is why their elimination promotes uncontrolled cell growth. 
Rb protein is encoded by RB gene that is the first tumor suppressor gene to be 
identified in hereditary retinoblastoma (Lee et al.’ 1987). The protein encoded by the RB 
gene, pRb，helps regulate the passage of cells from the Gi stage of the cell cycle into S 
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phase，during which DNA synthesis occurs. During most of Gj, the unphosphorylated 
pRb is bound to the transcription factor E2Fs (including E2F1, 2 and 3). The E2F-pRb 
complex binds to regulatory sites in the promoter regions of numerous genes involved in 
cell-cycle progression, acting as a repressor that blocks gene expression. Repression 
probably involves a histone acetylase that modulate chromatin architecture (Dyson, 1998; 
Luo et al., 1998). Activation of the Cdk leads to the phosphorylation of pRb, which can 
no longer bind the E2F protein. Loss of the bound pRb converts the DNA-boimd E2F into 
a transcription activator, leading to transcription of the genes being regulated for the 
progression of cells from Gi into S phase of the cell cycle (Dyson, 1998; Habour et al., 
1999). 
On the other hand, p53 tumor suppressor protein, which is regarded as guardian of 
the genome, plays a crucial role in cellular functions such as cell proliferation and 
apoptosis (Vousden and Lu, 2002). p53 is a transcription factor that activates the 
expression of other genes when cells subjected to ultraviolet light or chemical 
carcinogens leading to sustaining genetic damage. One of the genes activated by p53 
encodes a protein called p21 that inhibits the Cdk that normally drives a cell through the 
Gi checkpoint. As the level of p53 rises in the damaged Gi cell, expression of the p21 
gene is activated, and progression through the cell cycle is arrested. This gives the cell 
time to repair the genetic damage before it initiates DNA replication. When the genome 
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suffers damage that cannot be repaired, p53 can direct a genetically damaged cell along a 
pathway that leads to death by apoptosis (Bates et al, 1998). The p53 protein is thought 
to accomplish this by activating the expression of the bax gene, whose encoded product 
initiates apoptosis (Miyashita and Reed, 1995). 
Defects in the cell cycle regulatory mechanism such as uncontrolled cell 
proliferation, decreased cellular differentiation, ability to invade surrounding tissue, and 
ability to establish new growth at ectopic sites (metastasis) are the properties of cancer 
cells that are different from normal cells. Sporadic breast cancer is the most prevalent 
form of breast cancer and is thought to arise from the accumulation of multiple mutations 
or alternations in the expression of important cell regulatory genes. Amplification of 
oncogenes like c-myc (Strange et al, 1992)，ErbB-2/Her2 (Slamon et al, 1987), cyclin 
D1 (Bartkova et al., 1994), epithelial growth factor receptor (Humphreys and 
Hennighausen, 2000) and mutations of TP53 (Hartmann et al., 1997), and CDHl, the 
gene encoding E-cadherin (Vos et al” 1997), have been associated with breast cancer. The 
CCNDl gene encodes Cyclin Dl , an important regulatory molecule of the cell cycle. The 
overexpression of Cyclin Dl results in abnormal cell proliferation. Cyclin Dl 
amplification occurs in approximately 50% of breast cancer cases and its prognostic 
significance is under investigation (Bartkova et al, 1994; Gillett et al., 1994). As such, it 
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seems that the effect of some antitumor agents may contribute by maintenance of 
cell-cycle commitment and apoptosis induction on the defected cells. 
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Fig. 1.2 Regulation of Cell Cycle 
Progression through the cell cycle is positively regulated by the Cyclin-Cdks 
complex. There are also checkpoints (Gi, G2 and M) which control the cell 
progression from one phase to another. (Modified from Becker et al., 2003) 
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1.4 Regulation of Mitogen-Activated Protein Kinase (MAPK) Signaling Cascade 
Normal cellular behavior in multicellular organisms is tightly controlled by a 
complex network of signaling pathways that ensures that cells proliferate only when they 
are required by the body as a whole, for example, during development or wound healing. 
Cancer results from genetic alternations in these pathways, which normally manage the 
execution of developmental programs and the organismic response to extrinsic factors. A 
signal transduction cascade, starting from the membrane-anchored activated Ras protein 
and ending in nuclear gene transcription, was one of the first cascades described that 
possesses ability to regulate cell growth (Barbacid, 1987). Mutated Ras has been 
associated with the more chemoresistant tumors. Subsequent studies have found that an 
altered version of the ras gene is found in approximately 20 percent of all human cancers 
(Khleif et al, 1999). Ras protein functions as an on-off switch for mitogen-activated 
protein kinases (MAPKs) cascade that leads all the way from the outer surface of the 
plasma membrane to the DNA of the nucleus to stimulate the expression of genes whose 
products play a key role in activating the cell cycle, leading to the initiation of DNA 
synthesis and cell division (Li et al., 2001; Surh, 2003). In vitro and in vivo studies have 
shown that isolated activation of this pathway is both, necessary and sufficient for 
transformation (Troppmair et al., 1994; Cowley et al, 1994; Kerkhoff et al., 2000). 
In mammals, three major groups of MAPKs have been identified including 
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extracellular signal-related kinases (ERKs), c-Jun amino-terminal kinases/stress-activated 
protein kinases (JNKs/SAPKs) and p38. ERKl and ERK2 are the first identified MAPK, 
which are activated in response to diverse extracellular stimuli and by 
protooncogene-encoded proteins that induce proliferation (Sebolt-Leopold, 2000; 
Blume-Jensen and Hunter, 2001). The phosphorylation and activation of ERKs require 
the upstream dual-specificity kinases MAPK kinase 1 (MEKl) and MAPK kinase 2 
(MEK2) to phosphorylate both a threonine and a tyrosine in the activation loops of the 
ERKs. The phosphorylated and activated ERKs then translocate to the nucleus and 
phosphorylate a variety of substrates, such as the 90 kDa ribosomal S6 protein kinase 
(p90RSK), the cytosolic phospholipase A2, or several transcription factors including 
c-Myc, EIk-1, NF-IL6/C/EBPp/NFM, Tal-1, Ets-2，and possibly STAT proteins (Wada 
and Penninger, 2004). 
JNKs and p38 are two newly discovered MAPKs, which are activated predominantly 
by stress stimuli and pathogenic insults but in some cell types also by mitogens (Leppa, 
Bohmann, 1999; Johnson and Lapadat, 2002). JNK plays an important regulatory role in 
cell survival (Lopez-Ilasaca et aL, 1997; Antonyak et al.’ 1998), apoptosis (Xia et aL, 
1995; Maundrell et al., 1997; Yamamoto et al, 1999; Davis, 2000), tumor development 
(Johnson et al” 1996; Behrens et al” 2000)，and embryonic morphogenesis (Leppa and 
Bohmann, 1999). The JNK family includes three genes; JNKl and JNK2 are ubiquitously 
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expressed, while JNK3 is largely restricted to brain, heart and testis (Gupta et al., 1996). 
JNK has been reported to activate transcription factors in addition to c-Jun, such as ATF2, 
Elk-1，p53, and c-Myc (Davis, 2000), as well as non-transcription factors such as Bcl-2 
and BC1-XL (Maundrell et al.’ 1997; Yamamoto et al, 1999). JNKs are directly activated 
by the phosphorylation of tyrosine and threonine residues in a reaction that is catalyzed 
by the dual-specificity kinase MKK4 and MKK7 (also known as SEKl/JNKKl and 
SEK2/ JNKK2) (Holland et al., 1997; Lu et al, 1997; Toumier et al., 1997)，but by no 
other known MKKs. Although MKK4 and MKK7 are structurally related to MEKl and 
MEK2, MEKs do not activate JNKs and, conversely, MKK4 and MKK7 do not activate 
ERKs (Su and Karin, 1996; Woodgett et al” 1996). This implies that parallel and 
independent signaling cascades exist for MAPK and JNK activation to allow for a 
functional dichotomy among kinase cascades. It has also been shown that both MKK4 
and MKK7 are required for full activation of JNKs (Fleming et al” 2000; Wada et al, 
2001; Kishimoto et al., 2003). 
p38 signaling pathways are involved in a variety of cellular responses, and the 
outcomes of cellular response are varied and complicated. Similar to JNK pathways, the 
involvement of p38 in apoptosis is also diverse. It has been shown that p38 signaling 
promotes cell death (Sarkar et al., 2002; Porras et al., 2004), whereas it has also been 
shown that p38 cascades enhance survival (Park et al., 2002), cell growth (Juretic et al, 
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2001), and differentiation (Yosimichi et al, 2001). In most cases, p38 is simultaneously 
activated with JNKs (Werlen et al., 2003). At least four isoforms of p38 have been known: 
p38 a, P, y and 6 (Kyriakis and Avruch，2001). p38 is phosphorylated and activated by 
dual kinases MKK3 and MKK6 at threonine and tyrosine regions. p38 controls the 
function of transcription factors, kinases, or phosphatases such as ATF-2, MEF2, 
MAPKAPK, CDC25, or MSKl/2 (Davis, 2000; Bulavin et al., 2001; Chang and Karin, 
2001). 
Activation of ERKs has been linked to cell survival, whereas JNKs and p38 are 
linked to induction of apoptosis. This dichotomy, however, is an oversimplification, and 
the actual roles of each MAPK cascade are highly cell type- and context-dependent (Xia 
et al, 1995; Chang and Karin, 2001; Wada and Penninger, 2004). In fact, each molecule 
in this signaling cascade is activated by distinct pathways and transmits signals either 
independently or coordinately (Robinson and Cobb, 1997; Schaeffer and Weber, 1999; 
Davis, 2000; Chang and Karin, 2001). Abnormal or improper activation or silencing of 
this signaling cascade or its downstream transcription factors can generally result in 
uncontrolled cell growth, leading to malignant transformation (Surh, 2003). According to 
one of the recent researches, basal JNK activity is required for survival of MCF-7 cells 
and inhibition of JNK causes G2/M arrest and apoptosis (Mingo-Sion et al, 2004). 
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Regulation of the activity of JNK seems to be crucial in the growth inhibitory control on 
MCF-7 cells; thus, the JNK signaling pathway represents a potential target for therapeutic 
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Fig. 1.3 Regulation of MAPK Signaling Cascade 
Mitogen-activated protein kinases (MAPKs) play key roles in the cellular 
response to extracellular stimuli. Three major mammalian MAPK subgroups 
have been identified: ERK, JNK and p38. (Modified from Surh, 2003) 
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1.5 Programmed Cell Death (or Apoptosis) 
Apoptosis is a genetically controlled event that is essential for embryonic 
development, immune-system function and the maintenance of tissue homeostasis in 
multicellular organisms (Jacobson et aL, 1997; Savill and Fadok, 2000). An inability of 
cells to undergo apoptotic cell death has been implicated in the development of malignant 
tumors (Steller，1995). Apoptosis is ultimately caused by cysteine aspartyl-specific 
proteases, or caspases (Thomberry and Lazebnik, 1998)，which is defined by a pattern of 
molecular and morphological changes, such as cell shrinkage, formation of apoptotic 
bodies, loss of mitochondrial membrane potential, DNA fragmentation, etc. 
(Darzynkiewicz, 1995a; Darzynkiewicz et al, 1995b; Darzynkiewicz et al； 1997; 
Gilmore et al” 2000)，that result in the "packaging" and rapid removal of the dying cells. 
Cells that are committed to the apoptotic programme after developmental cues, stress or 
infection are removed by phagocytosis to prevent a host immune response (Savill and 
Fadok, 2000). However, the absolute requirement for caspase activation in apoptosis is no 
longer considered dogma. Caspase-independent cell death has been defined as the loss of 
cell viability that is induced by proapoptotic conditions, and which proceeds despite the 
inhibition or disruption of caspase function (Canda et al., 2004; Chipuk and Green, 2005). 
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1.5.1 Regulation of Caspase-Dependent Apoptosis 
Caspases are a family of intracellular proteases that function in a proteolytic 
cascade where each caspase can either activate itself of other caspases. Fourteen caspases 
have been identified in mammalian cells, of which 11 enzymes are known in humans. 
These enzymes are synthesized as precursor proenzymes that must be cleaved at 
conserved aspartate residues to generate the active tetrameric enzyme (Nicholson, 1999). 
To some extents, this cascade involves initiator caspases (caspase-2, -8，-9 and -10) 
characterized upstream of effector caspases (caspase-3, -6 and -7). Other enzymes 
(caspase-1, -4, -5, -11，-12 and -14) are mainly involved in cytokine maturation and 
inflammation (Kumar, 1999; Nicholson, 1999). There are two pathways including the 
extrinsic and intrinsic apoptotic pathways (Fig. 1.4) by which caspase activation is 
triggered. 
a. Extrinsic Apoptotic Pathway/Death Receptor Pathway 
The extrinsic apoptotic pathway is activated by the engagement of death receptors 
on the cell surface with their ligands, such as the CD95/Fas, tumor-necrosis-factor-a 
(TNF-a), TNF-related apoptosis-inducing ligand (TRAIL). A death-inducing signaling 
complex consisting of Fas, the Fas receptor, the adaptor protein FAS-associated death 
domain (FADD) and procaspase-8 is formed at the cell membrane, leading to activation 
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of initiator caspase-8. Caspase-8 can either directly cleave and activate the effector 
caspase-3 (type I cells) or cleave the carboxy-terminal part of a BH3 domain-only 
proapoptotic member of the Bcl-2 family designated Bid (type II cells) (Li et al., 1998b; 
Luo et al” 1998; Scaffidi et al.’ 1999). In turn, translocation of the truncated Bid (tBid) to 
the mitochondria activates, in combination with Bax, the intrinsic apoptotic pathway 
described below. 
b. Intrinsic Apoptotic Pathway/Mitochondria-Dependent Pathway 
The intrinsic apoptotic pathway is triggered by various extracellular and intracellular 
stresses, such as growth-factor withdrawal, hypoxia, DNA damage, and oncogene 
induction. Signals that are transduced in response to these stresses converge mainly on the 
mitochondria. A series of biochemical events is induced that results in the 
permeabilization of the outer mitochondrial membrane (Kluck et al.’ 1999), the release of 
cytochrome c and other apoptotic molecules, the formation of the apoptosome which is a 
large protein complex that contains cytochrome c, apoptotic protease activating factor-1 
(Apaf-1) and caspase-9, and caspase activation (Budihardjo et al., 1999). Among these 
processes, only the permeabilization step is regulated, in that antiapoptotic members of 
the Bcl-2 family can stop the march towards apoptotic death (Cory and Adams, 2002). 
Once cytochrome c is released, however, the downstream cascade of caspase activation is 
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irreversible (Goldstein et al” 2000). This pathway can also be amplified by caspase-8- or 
caspase-3-mediated cleavage of Bid to tBid that then activates Bax. Apart from mediating 
this auto-amplification loop, Bid connects the extrinsic to the intrinsic apoptosis pathway 
(Herr and Debatin, 2001; Daniel et al, 2003). 
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Fig. 1.4 Regulation of Caspase-Dependent Apoptosis 
The extrinsic apoptotic pathway (left) is induced by death receptor 
ligands, which in turn leads to the activation of initiator caspase-8. In 
contrast, the intrinsic apoptotic pathway (right) is triggered by apoptotic 
stimuli, which leads to the activation of initiator caspase-9. Both of them 
converge to the activation of the executioner caspases leading to cell 
death. (Modified from Daniel etal., 2003) 
31 
Chapter 1 
1.5.2 Regulation of Caspase-Independent Cell Death 
In some cells, cytochrome c release could inhibit the respiratory chain in the 
mitochondria, resulting in ATP depletion that precludes procaspase-9 recruitment by 
Apaf-1. This situation prevents caspase-dependent features of apoptosis such as 
oligonucleosomal DNA fragmentation and advanced chromatin condensation. The death 
phenotype observed in such a situation could involve the 57-kDa flavoprotein apoptosis 
inducing factor (AIF) and endonuclease G (endoG), which translocate from the 
mitochondria to the nucleus and trigger ATP- and caspase-independent nuclear changes 
(Susin et al., 1999b). Inhibition of the respiratory chain also enhances generation of ROS 
that contribute to cell damage. Changes in mitochondrial function may also be 
responsible for cytoplasmic acidification that was reported as an early event during 
apoptosis (Schendel et al, 1998; Kroemer and Reed, 2000). 
1.5.3 Bcl-2 Family Proteins in Modulation of Cell Death 
The Bcl-2 family of intracellular proteins is the central regulator of caspase activation, 
and its anti- and proapoptotic members arbitrate the life-or-death decision (Cory and 
Adams, 2002). Although the overall amino acid sequence homology between the family 
members is relatively low, they contain highly conserved domains, referred to as BH 
(Bcl-2 homology) domain (BHl-4), that are essential for the homo- and hetero-complex 
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formation, as well as for their cell-death-inducing capacity. Thus, Bcl-2 family members 
act like checkpoints through which survival and death signals must pass before they 
determine the cell fate. Structural and functional analyses revealed that the growing 
Bcl-2-homologous genes can be divided into at least three distinct subfamilies: Bcl-2 and 
Bax and BH3-only subfamilies (Daniel et al, 2003). 
a. Bcl-2 Subfamily 
The Bcl-2 subfamily including Bcl-2 and BC1-XL prevents cell death and functions as 
potential oncogenes. This antiapoptotic subfamily, which possesses up to four conserved 
BH domains designated BHl to BH4, modulates cell death in part by either disturbing the 
formation of the apoptosome by affecting the mitochondrial compartmentalization of 
cytochrome c and several other proteins or interfering with the function of this 
apoptosome through a direct interaction of Bcl-2 or BC1-XL with Apaf-1 (Budihardjo et al., 
1999; Daniel et al.’ 2003). Expression of Bcl-2 proteins also stabilizes the mitochondrial 
membrane potential by regulating the proton flux, inhibiting the generation of ROS, and 
preventing the cytoplasmic acidification (Schendel et al, 1998; Kroemer and Reed, 2000). 
Thus, Bcl-2 proteins can be envisioned as general regulators of mitochondrial physiology. 
33 
Chapter 1 
b. Bax Subfamily 
The Bax subfamily including Bax and Bak, which possesses at least three BH 
domains, encourages cell demise and behaves as tumor suppressor genes. During 
induction of the mitochondrial pathway, Bax and Bak become activated and undergo a 
conformational switch in the N-terminus and the C-teraiinus that results in redistribution 
of Bax to the mitochondria. Activation of Bax results in insertion of Bax into the outer 
mitochondrial membrane. Bax translocation to the mitochondria coincides with 
oligomerization of Bax to multimeric complexes (Eskes et al, 2000). Such Bax oligomers 
possess channel-forming properties that are associated with ion fluxes and consecutive 
loss of the mitochondrial membrane potential. Besides, the perforation leads to the release 
of apoptogenic factors such as cytochrome c, which forms the apoptosome, and 
Smac/DIABLO and HtrA2/0mi, which enhance caspase-9 activity by neutralizing the 
inhibitor of apoptosis proteins (lAP) (Kroemer and Reed, 2000). In contrast, Bak resides 
constitutively in the mitochondrial membrane and the endoplasmic reticulum, where it 
oligomerizes upon activation (Wei et al., 2000; Borner，2003). 
c. BH3-0nly Subfamily 
The BH3-only proteins are designated as they carry only one of the signature 
domains of Bcl-2, the BH3 domain. The well-studied members of this subfamily include 
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Bad and Bid. Recent studies indicate that BH3-only proteins，essentially depending on 
either Bax or Bak, act as mediators that link various upstream signals, including death 
receptors and DNA damage signaling, to the mitochondrial and ER pathway (Daniel et al., 
2003). 
Proapoptotic Bad protein interacts via its BH3 domain with Bcl-2 and BC1-XL to 
facilitate the actions of apoptotic stimuli. In fact, Bad is inactivated upon phosphorylation 
of Ser-155 within the BH3 domain through the antiapoptotic Akt kinase (Datta et al., 
2000). This leads to sequestration of the phosphorylated Bad in the cytosol through 
binding to 14-3-3 proteins. The sequestration of Bad, in turn, was shown to enhance the 
antiapoptotic properties of BC1-XL. This appears to occur through phosphorylation and 
binding of Bad to 14-3-3 proteins instead of binding of the unphosphorylated Bad to 
BC1-XL. Thus phosphorylation of Bad impairs its proapoptotic potency (Daniel et al., 
2003). 
During apoptosis mediated upon ligation of death receptors, the BH3-only protein 
Bid is proteolytically cleaved by caspase-8 to a proapoptotic form, tBid, from an inactive 
form. tBid appears to interact physically with Bax to mediate a conformational change in 
the Bax N-terminus (Desagher et al., 1999). This event triggers insertion of cytosolic Bax 
into the outer mitochondrial membrane (Eskes et al, 2000). Thus Bid links death-receptor 
signaling to the mitochondrial pathway. Interestingly, Bid cleavage can occur in a death 
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receptor-independent manner downstream of the mitochondrial through a caspase-3- and 
-8-dependent mechanism (Belka et al., 2000). Thus caspase-3, caspase-8 and Bid 
cleavages mediate a positive-feedback loop that is required for full cytochrome c release 
during anticancer drug-induced apoptosis (von Haefen et aL, 2003). 
In an overall scenario, the development of malignant tumors results from deregulated 
proliferation or inability of cells to undergo apoptotic cell death. Anticancer drugs inhibit 
proliferation and induce apoptosis in sensitive tumor cells (Herr and Debatin, 2001). 
Although, apoptosis is not the only mode of cell death triggered by anticancer drugs, 
better understanding of the apoptotic pathways and their modulations by various negative 
and positive signals simulated by anticancer agents may prove particularly valuable in 
cancer therapy. The genes and their proteins involved in cell-death regulation could be 
used as new targets for anticancer drugs, and simultaneous signals may be manipulated to 
increase the efficacies of conventional cancer treatments. 
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1.6 In Vivo Antitumor Screening System 
The development of inbred strains of mice in the early part of the 20 century led to 
the use of transplantable tumors for the screening of very large numbers of compounds, 
both natural and synthetic, for experimental antitumor activity. Such screening led to the 
identification of clinically useful drugs at a rate of approximately one every 2 years 
(Baguley and Kerr, 2002). The researchers always use mice as their animal model, since 
they are easy to handle and have a rapid breeding cycle. The mouse models of particularly 
importance to anticancer drug screening are BALB/c and ICR mice. Spontaneous or 
carcinogen-induced tumors in these strains could be transplanted from one inbred mouse 
to another, allowing repeated testing of potential anticancer drugs (Stock, 1954). In 
addition, the discovery of the athymic nude mouse, which had lost its ability to mount a 
cell-mediated immune response, allowed the testing of new drugs against human tumor 
material growing as xenografts in such mice (Rygaard and Povlsen, 1969). The best sites 
for tumor cells implantation are intramuscular (i.m.) in the leg or subcutaneous (s.c.) over 
the lower back of the mice, as the tumor size can be measured easily (Begg, 1987). The 
anti-tumor effects are usually evaluated by using different parameters, such as regression 
of tumor and mortality of the tumor bearing mice. 
37 
Chapter 1 
1.7 Aims of the Present Study 
Cancer chemoprevention entails the uses of natural or synthetic agents to retard, 
block, or reverse the process of carcinogenesis. Phytochemicals are the non-nutritive 
components in plant-based diet and have been suggested over the past years as safe and 
effective anticarcinogenic agents (Surh, 2003). Chlorophyllin, which is a semi-natural 
phytochemical, has great potential in overcoming the multistep carcinogenesis but the 
exact mechanistic actions are not yet fully elucidated. In this study, the anticancer effects 
of CHL on human breast carcinoma MCF-7 cells were focused, which have not yet been 
reported by other researchers. The application of flow cytometric and Western blot 
techniques in the studies of cell proliferation, apoptosis, and their regulatory gene 
expression is the mode of choice to provide novel and important information on how 
CHL exerts its in vitro anticancer activity on the breast cancer cells. Transplantable 
MCF-7 solid tumors as xenografts in athymic mice allow further testing of the anticancer 
potency of CHL in vivo. We anticipate that the results from this study would allow more 
understandings on the anticancer mechanisms of CHL. As CHL is low-cost and easily 
available and lacks of any observable adverse effect, it deserves our further research and 
development as a potent cancer chemopreventive and therapeutic agent. 
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Chapter 2 In Vitro Studies of the Anticancer Effect of Chlorophyllin 
2.1 Introduction 
Cell growth is a balance between cell proliferation and cell death. There are different 
methods assessing the effects of an antitumor agent on tumor cell proliferation and 
viability. Among these methods, measuring the cellular DNA synthesis and metabolic 
activity are common for indicating the cell proliferation and cell growth, respectively. 
In 1983，Mosmann described a rapid colorimetric assay for assessing cell 
proliferation and cell death, in terms of the level of cellular metabolic activity. Cellular 
damage will inevitably result in a loss of the ability of a cell to provide energy for its 
metabolic functions. Based on this premise, cellular metabolic activity is a good indicator 
of cell proliferation and cell death. This assay, which is usually applied for adhesive cells, 
is based on the cleavage of the yellow water-soluble substrate 
3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) into a water 
insoluble dark blue formazan product by mitochondrial dehydrogenases in the living cells 
(Mosmann, 1983). The amount of formazan produced is directly proportional to the 
number of viable cells (Gerlier and Thomasset, 1986). 
Measuring [^H]-thymidine incorporation into cellular DNA is a commonly used 
method for quantifying level of cell proliferation. Since chromosome replication is 
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accompanied by the incorporation of soluble nucleotide precursors into newly synthesized 
DNA during the S phase in cell cycle, monitoring of the thymidine incorporation provides 
a direct measurement of the cell proliferation. In this method, dividing cells are pulsed 
with radioactive exogenous precursor [^H]-thymidine, the amount of radioactivity 
incorporated into the cellular DNA is determined by harvesting the cells on a glass-fiber 
filter followed by liquid scintillation counting. Due to the potential hazards associated 
with the use of radioactive substances, non-radioactive method alternative to the 
[^H]-thymidine incorporation was developed (Takeyoshi et al., 2001). In this alternative 
method, 5-bromo-2 ‘ -deoxyurdine (BrdU), which is an analogue of pyrimidine, is applied 
instead of [^H]-thymidine which incorporates into the cellular DNA of proliferating cells. 
Diaz et al. (2003) reported previously that CHL directly retarded growth of the 
human colon cancer HCT116 cells. To explore the effects of CHL on controlling growth 
of other human cancer cells, MTT assay was applied in the present study for the 
preliminary screening of the cytotoxic effects of CHL on different human cancer cells. 
Human breast carcinoma MCF-7, which was found to be most responsive to the CHL 
treatment, was then subjected to the BrdU incorporation assay to study the cytostatic 
effect of CHL on proliferation of the cells. The concentration of CHL with 50% inhibition 
on the cell proliferation was then estimated for the further investigations on the 
mechanistic actions accounting for its growth inhibitory effects on the breast cancer cells. 
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In an overall scenario, the development of malignant tumors results from 
deregulated proliferation or an inability of cells to undergo apoptotic cell death (Steller, 
1995). Although CHL was shown to retard both cell proliferation and viability of the 
breast cancer cells, the underlying mechanisms remain unclear. Thus, the mechanisms for 
the growth-inhibitory activity of CHL were further explored in this study. The 
proliferation of eukaryotic cells is determined ultimately by the progression of cells 
through the cell cycle (Kohn et al., 1994; Tsurasawa and Fujimoto, 1995). Any factors 
that affect the genes and/or proteins regulating the cell-cycle processes will cause a delay 
or an arrest of the cell-cycle phase, leading to delayed proliferation (Tinnemans et al., 
1995; Lai et al., 1996; Tatebe et al., 1997). Cell-cycle analysis provides a useful tool for 
the study of relevant cellular targets. Thus, how CHL affected the cell-cycle profile of the 
breast cancer cells was evaluated in this study with the application of flow cytometric 
technology. DNA-flow cytometric analysis (detailed in Section 2.1.1) was applied to 
investigate the cytotoxic effects of CHL on the breast cancer cells in terms of cell-cycle 
distribution. In addition, the time effects of CHL were also investigated on the breast 
cancer cells. 
Cyclins are cell-cycle regulators whose levels oscillate in an orderly manner during 
the course of cell cycle and control the cell-cycle progression (Lukas et al” 1995; Pines, 
1995). Our previous findings illustrated that CHL inhibited the proliferation of MCF-7 
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cells, possibly by preventing the cell-cycle progression so that the cells were accumulated 
or arrested at the GQ/GI phase during the early phase of treatment. Thus, how C H L 
affected the expression of cyclin and hence the blockage of cells to enter the subsequent 
cell-cycle phase was evaluated. D-type cyclins collectively control the cell-cycle 
progression by activating their cyclin-dependent kinase partners Cdk4 and Cdk6. The 
activated Cdks then phosphorylate the retinoblastoma protein so that the E2F family of 
transcription factors are released, leading to the cell-cycle progression through G! into S 
phase (Morgan, 1997; Sherr and Roberts, 1999). Since the induction of Cyclin D1 is often 
the rate-determining step in the formation of Cyclin D-Cdk4/6 complexes，the 
mechanisms that control the induction of Cyclin D1 are thought to play a significant role 
in controlling the cell-cycle progression through Gi phase (Welsh et al.’ 2001). Cyclin D1 
is strongly implicated in mammary oncogenesis, and its overexpression was observed in 
some 50% of human breast cancer (Bartkova et al., 1994; Gillett et al, 1994). Cyclin D1 
overexpression is seen in all histologic types of breast cancer and at all stages from 
carcinoma in situ through metastatic disease but not in premalignant lesions 
(Weinstat-Saslow et al., 1995; Gillett et al” 1996). Transgenic mice that overexpress 
Cyclin D1 in mammary tissue develop breast cancers (Wang et al., 1994) and Cyclin 
D1-deficient mice are resistant to breast cancers induced by neu and ras oncogenes (Yu et 
al., 2001). In the present study, the cells treated with CHL were analyzed for the Cyclin 
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Dl expression by Western blot analysis (detailed in Section 2.1.2) as the first step to 
understand the mechanistic actions leading to the antiproliferative effects of CHL in the 
breast cancer cells. 
The Gi phase of cell cycle is the site of integration of many extracellular 
growth-regulatory signals (Sherr and Roberts, 1999). Cyclin Dl is one of the major 
targets of several growth-stimulatory signaling pathways and is directly linked to Gi 
cell-cycle progression (Derijard et al, 1994). The first part of the results from this study 
indicated that CHL downregulated the expression of Cyclin Dl . To further investigate the 
upstream signaling cascade that CHL modulated for the decreased cell proliferation, both 
JNK and c-Jun were examined using Western blot analysis. Their stage of activation was 
also determined by using specific antibodies for their phosphorylated forms. It is 
recognized that Cyclin Dl can be induced by the ectopic expression of c-Jun (Albanese et 
al., 1995), which is the most-studied substrate of c-Jun N-terminal 
kinases/stress-activated protein kinases (JNKs/SAPKs) (Rennefahrt et al, 2005). JNK, 
which is a subfamily member of the mitogen-activated protein kinases (MAPKs), plays 
an important regulatory role in cell survival (Lopez-Ilasaca et al, 1997; Antonyak et al, 
1998)，apoptosis (Xia et al., 1995; Maundrell et cd” 1997; Yamamoto et al., 1999; Davis, 
2000), tumor development (Johnson et al, 1996; Behrens et al., 2000)，and embryonic 
morphogenesis (Leppa and Bohmann, 1999). The phosphorylated JNK, i.e. the active 
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form, translocates to the nucleus where it phosphorylates c-Jun, which is one of the 
members of the activator protein-1 (AP-1). AP-1 is a transcription factor that regulates 
expression of genes, such as cyclin Dl, p53, p21 cipiAVafi，pigARF，and pl6, involving in 
cellular adaptation, differentiation and proliferation (Jochum et al.’ 2001; Shaulian and 
Karin, 2001; Vogt, 2001). Besides participating in the regulation of cellular proliferation, 
a number of studies have also implicated the involvement of both JNK activation and 
c-Jun phosphorylation in the induction of apoptosis following stress (Xia et al” 1995; 
Davis, 2000). While the basal activity of JNK is generally low in cells maintained under 
normal growth conditions, JNK can be activated by growth factors, such as epidermal 
growth factor and platelet-derived growth factor, via mechanisms that appear to rely on 
phosphoinositide 3-kinase (Minden et al.’ 1994; Bost et al., 1997; Logan et al., 1997; 
Lopez-Ilasaca et al., 1997; Antonyak et al, 1998). Furthermore, it has been reported that 
the inhibition of constitutive JNK activity by the JNK-specific inhibitor SP600125 
induces growth arrest in myeloma cell lines (Hideshima et al., 2003). Most recently, 
Mingo-Sion et al (2004) also suggested that basal JNK activity is required for survival of 
MCF-7 cells and inhibition of JNK causes G2/M arrest and apoptosis. Therefore，the 
effects of CHL on the expression and the activation stage of JNK and c-Jun were 
investigated in this study to provide insights into the mechanisms for the 
growth-inhibitory activity of CHL through a JNK-mediated signal transduction pathway. 
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With respect to the decrease in cell proliferation and viability, the inhibitory effects 
of CHL on the breast cancer cell growth may be a result of slow cell-cycle progression 
and induction of cell death, respectively. Apart from studying cell-cycle modulation, the 
induction of cell death, which is one of the important anticancer therapeutic routes, by 
CHL in MCF-7 cells was also investigated by the DNA-flow cytometric analysis 
concerning the DNA fragmentation. Two of the best studied and phenotypically clearly 
distinguishable forms of cell death are apoptosis and necrosis, which are characterized by 
typical morphological criteria. Necrosis, which is caused by non-physiological extremes 
in the cellular environment, is a passive and unregulated process which typically occurs 
after excessive damage by physical or chemical injury, cells display cytoplasmic 
vacuolization and swelling of the cytoplasm and organelles concomitant with a loss of 
membrane integrity. In necrotic cells, the loss of membrane integrity leads to the release 
of cellular content and results in inflammation of surrounding tissues (Darzynkiewicz et 
al., 1997; Soldani and Scovassi, 2002). Apoptosis, in contrast, is an active, 
energy-dependent process, which involves the execution of a series of pre-programmed 
events that are tightly regulated by genes inducing cell death and the main features of 
apoptosis include cell shrinkage, formation of apoptotic bodies, loss of mitochondrial 
membrane potential, DNA fragmentation, etc. (Darzynkiewicz, 1995a; Darzynkiewicz et 
al., 1995b; Darzynkiewicz et al, 1997; Gilmore et al.’ 2000). To investigate the modes of 
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cell death induced by CHL in the MCF-7 cells, 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), which 
is a cationic dye exhibits potential-dependent accumulation in mitochondria, was applied 
to examine the mitochondrial membrane potential. It is well known that several stimuli 
induce a decrease in the mitochondrial membrane potential, which precedes the nuclear 
fragmentation in apoptosis (Castedo et al., 1996). Such information provides insights, 
additional to the DNA fragmentation, into the mode of cell death that CHL induced in the 
breast cancer cells. 
Apoptosis signaling induced by anticancer drugs converges in the activation of 
intracellular caspases and their modification of protein substrates within the nucleus and 
cytoplasm (Herr and Debatin, 2001). The cleavage of poly(ADP-ribose) polymerase 
(PARP) during apoptosis, first described by Kaufmann et al (1993)，in cells treated with 
different drugs, is attributed to caspases. During apoptotic cell death, precocious and 
transient stimulation of PARP causes poly(ADP-ribose) accumulation in the early 
apoptotic cells (Donzelli et al.’ 1997; Rosenthal et al” 1997). Furthermore, PARP 
cleavage by caspases is responsible for the inactivation of the poly(ADP-ribosylation) 
process, which is a post-translational modification of proteins that, in eukaryotic cells， 
plays a crucial role in DNA repair and replication, transcription and cell death, and 
represents a cellular emergency reaction (D'Amours et al., 1999; Scovassi and Poirier, 
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1999; Ziegler and Oei, 2001). Therefore, in this study, to investigate the mode of cell 
death that CHL induced for the decreased cell viability, DNA fragmentation shown as the 
presence of subGi cells in DNA histograms, change of mitochondrial membrane potential, 
and PARP cleavage were measured. The PARP study also provided insights into the 
caspase-dependency of the CHL-induced cell death. 
Apoptosis, or programmed cell death, is often impaired in cancer, which limits the 
outcome of conventional therapy. Our previous investigation demonstrated that the 
CHL-induced MCF-7 cell death was mediated by apoptosis. The next step is to 
characterize the molecular pathways in the CHL-induced apoptosis. Human breast 
carcinoma MCF-7 cell line is one of the malignant breast cancer cell lines which have a 
weak bax gene expression (Sakakura et al, 1997). Overexpression of Bcl-2, BC1-XL, or 
other antiapoptotic homologues or loss of proapoptotic Bax or Bak is a common feature 
of human tumors. Apart from being involved in tumorigenesis of which deregulation of 
Bcl-2 homologues is required to counteract the proapoptotic properties of oncogenes, 
expression and mutation analyses in human tumors revealed that overexpression of 
antiapoptotic Bcl-2 family members or loss of Bax homologues is associated with the 
acquisition of clinical resistance to cancer therapies (Schelwies et al.，2002; Mrozek et al, 
2003). 
The Bcl-2 family proteins are central regulators of apoptosis because they integrate 
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diverse survival and death signals that are generated outside and inside the cell (Strasser 
et al., 2000; Adams and Cory, 2001). The Bcl-2 subfamily, including Bcl-2 and BC1-XL, 
prevents cell death and functions as potential oncogenes. This antiapoptotic subfamily 
modulates cell death in part by either affecting the mitochondrial compartmentalization of 
cytochrome c to form the cytochrome c/Apaf-l/caspase-9 apoptosome and several other 
proteins or interfering with the function of this apoptosome through a direct interaction 
with Apaf-1 (Budihardjo et al, 1999). Expression of Bcl-2 proteins also stabilizes the 
mitochondrial membrane potential by regulating the proton flux, inhibits generation of 
reactive oxygen species, and prevents cytoplasmic acidification (Schendel et al., 1998; 
Daniel et al” 2003). Thus, Bcl-2 proteins can be envisioned as general regulators of 
mitochondrial physiology. It is believed that Bax protein can form homodimer to enhance 
the actions of apoptotic stimuli, or associate with Bcl-2 protein as heterodimer to abolish 
the Bcl-2 death-sparing activity (Oltvai et al.，1993; Salomons et al, 1997). The lack of 
Bax in MCF-7 cells (Sakakura et al., 1997) leads to the investigation of the potential 
involvement of proapoptotic Bad in the CHL-induced apoptosis in this study, which also 
interacts via its BH3 domain with Bcl-2 and BC1-XL to facilitate the actions of apoptotic 
stimuli. In fact, Bad is inactivated upon phosphorylation of Ser-155 within the BH3 
domain through the antiapoptotic Akt kinase (Datta et al., 2000). This leads to the 
sequestration of the phosphorylated Bad in the cytosol through binding to 14-3-3 proteins. 
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The sequestration of Bad, in turn, enhances the antiapoptotic properties of BC1-XL. The 
expressions of Bcl-2, BC1-XL and Bad proteins in the MCF-7 cells after the CHL treatment 
were measured that provide insights into the signal transduction pathways of the induced 
mitochondrial membrane depolarization and the ultimate apoptosis in the breast cancer 
cells. 
In most studies, apoptotic signaling and execution pathways involve the activation of 
caspases, which in turn cleave the key protein substrates. On the basis of primary 
structure, procaspases can be divided into two classes, caspase-2, -8, -9 and -10，which 
contain long amino-terminal prodomains and act as initiators, and caspase-3, -6 and -7, 
with short prodomains that act as effectors (Salvesen and Dixit, 1997; Thomberry and 
Lazebnik, 1998). There are two well-studied pathways in apoptosis, the 
mitochondrial-initiated pathway and the cell surface death receptors pathway (Strassar et 
al., 2000). Activation of the initiator caspases corresponding to these two pathways leads 
to the direct or indirect activation of the executioner caspases, including caspase-3, -6 and 
-7 (Slee et al.’ 2001). Activation of executioner caspases and the subsequent generation of 
feedback amplification loops lead to the proteolysis of cytoplasmic and nuclear 
polypeptide substrates, including major structural elements of the cytoplasm and nucleus, 
proteins involved in DNA repair, and several different protein kinases, which ultimately 
results in cell death (Eamshaw et al., 1999). It was shown previously that MCF-7 cells 
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have lost caspase-3 expression because of a 47-bp deletion within exon 3 of the CASP-3 
gene (Janicke et al., 1998). Caspase-3, which is an important effector caspase, although 
required for some of the typical hallmarks of apoptosis (Janicke et al.’ 1998; Porter and 
Janicke, 1999; Bratton et al., 2000), seems to be dispensable for cell death induced by a 
variety of stimuli, such as TNF，CD95, or anticancer drugs (Janicke et al., 1998; Porter 
and Janicke, 1999; Janicke et al.’ 2001). This is consistent with the observations that other 
effector caspases, such as caspase-6 or -7’ can compensate for the lack of caspase-3, at 
least to some extent, in a stimulus- and cell type-dependent manner (Zheng et al, 2000). 
As shown previously, the CHL-induced apoptosis in the MCF-7 cells involved PARP 
cleavage, indicating that the cell death should be caspase-dependent. To confirm this 
observation and have further studies on the involvement of caspases in the CHL-induced 
apoptosis, effects of CHL on the activations of some initiator and effector caspases and 
retardation of the induced apoptosis by some specific caspase inhibitors were determined. 
Consequently, the caspase cascade was evaluated by Western blot analysis and the 
application of specific caspase inhibitors in order to understand the mechanistic actions 
leading to apoptosis induction by CHL in the breast cancer cells. 
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2.1.1 DNA-Flow Cytometric Analysis 
One of the important applications of DNA-flow cytometry is to study the hypo- and 
hyperdiploidy of cancer cells (Shankey et aL, 1993), which is based on the measurement 
of the DNA-binding dye, propidium iodide (PI), that stains the cellular DNA specifically 
in a stoichiometric manner (i.e. the extent of staining is directly proportional to the 
amount of DNA within the cells). After staining the fixed cells with PI, flow cytometer 
can rapidly and accurately measure the red fluorescence emitted from the cellular DNA of 
each individual cell, excited by 488 nm laser beam. A DNA histogram can thus be 
generated to illustrate the DNA content semi-quantitatively of the entire cell population. 
DNA histogram (Fig. 2.1) is the frequency distribution conducted from the relative 
PI fluorescence of thousands of individual cells, detected by the photomultiplier tubes of 
the flow cytometer. The total (area) fluorescence of the light pulse from each signal is 
converted into a digital number that corresponds to a channel number. The number of 
counts per channel (y-axis) corresponding to the relative number of cells, is plotted by the 
increasing channel numbers on the x-axis corresponding to the increased red fluorescence 
(DNA content). Therefore, the red fluorescence intensity histogram represents the 
DNA-content distribution of cells from the cell population. 
The DNA histogram comprises two peaks separated by a trough. The first peak 
represents the GQ/GI phase; in this period, the DNA content is the least in the cell cycle. 
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The second peak represents the G2/M phase in which the DNA content of the cells is 
duplicated and is ready to divide into daughter cells. In between these two peaks is the S 
phase in which DNA is actively synthesized. The objective of DNA histogram analysis is 
to obtain a reasonable approximation for the population of cells in the Go/Gi, S and G2/M 
phases of cell cycle, which acts as a crude index of the proliferative activity of the tumor. 
In some circumstances, there is a peak with lower D N A content on the left of GQ/GI 
peak referring to the subGi or apoptotic peak (Ap). During apoptosis, endonuclease(s) 
may be activated and results in the DNA fragmentation at intemucleosomal regions 
generating nucleosomal and oligonucleosomal DNA (McConkey et al., 1996; Tanuma 
and Shiokawa, 1996). These DNA fragments are then extracted so that the remaining 
DNA inside the apoptotic cells becomes lower in content than that in the Gi cells. The 
intensity of the red fluorescence emitted from the apoptotic cells is thus lower so that the 
cells exist as the apoptotic peak on the left of Gi peak in DNA histogram. Therefore, by 
analyzing DNA content of the cells, not only cell-cycle progression but also the incidence 
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Fig. 2.1 A DNA Histogram of Flow Cytometry. 
A eukaryotic cell cycle is divided into Go/Gi, S and G2/M phases. After 
some apoptotic stimuli, the sub Gi or apoptotic peak (Ap) may also be 
found on the left of the Go/Gi peak. (Obtained from MultiCycle software) 
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2.1.2 Western Blot Analysis 
Electrophoresis is one of the most widely used techniques to resolve proteins, which 
depends on the ability of charged molecules to migrate when placed in an electric field. 
The electrophoretic separation of proteins is usually accomplished using polyacrylamide 
gel electrophoresis (PAGE), driven by an applied current through a gelated matrix, which 
is composed of polymers of a small organic molecule (acrylamide) that are cross-linked to 
form a molecular sieve. Separations are typically carried out using alkaline buffers, which 
make the proteins negatively charged and cause them to migrate toward the positively 
charged anode at the opposite end of the gel. Following electrophoresis, the proteins in 
the gel can be transferred by a second electrophoretic procedure to a membrane to form a 
blot. Proteins become absorbed onto the surface of the membrane in the same relative 
positions they occupied in the gel. In a Western blot, the proteins on the membrane are 
identified by their interaction with the specific antibodies. 
The relative movement of proteins through a polyacrylamide gel depends on the 
charge density (charge per mass) of the molecules. The greater the charge density, the 
more forcefully the protein is driven through the gel, and thus the more rapid its rate of 
migration. Although charge density is an important factor in PAGE, size and shape of the 
molecules also play a role. Polyacrylamide forms a cross-linked molecular sieve that 
entangles proteins passing through the gel. The larger the protein, the more it becomes 
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entangled, and the slower it migrates. PAGE is usually carried out in the presence of the 
negatively charged detergent sodium dodecyl sulfate (SDS), which binds in large numbers 
to all types of protein molecules. The electrostatic repulsion between the bound SDS 
molecules causes the proteins to unfold into similar rodlike shape, thus eliminating 
differences in shape as a factor in separation. The number of SDS molecules that bind to a 
protein is roughly proportional to the protein's molecular mass. Consequently, each 
protein species, regardless of its size, has an equivalent charge density and is driven 
through the gel with the same force. As a result, proteins become separated by 
SDS-PAGE on the basis of a single property, which is the molecular mass. 
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2.2 Materials and Methods 
2.2.1 Maintenance of Cell Lines 
The human cancer cell lines including human breast carcinoma MCF-7, cervical 
carcinoma HeLa, hepatocellular carcinoma HepG2 and laryngeal carcinoma HEp-2 were 
used to study the cytotoxic and cytostatic effects of CHL in this study. All cell lines were 
provided by American Type Culture Collection (Rockville, MD). MCF-7 and HepG2 cells 
were grown in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO), while HeLa 
and HEp-2 cells were grown in Minimal Essential Medium (MEM) (GIBCOBRL Life 
Technologies Inc., Rockville, MD). All media were supplemented with 0.2% sodium 
bicarbonate (Sigma), 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 
昭/ml of streptomycin and 0.25 |ig/ml amphotericin B，and MEM was additionally 
supplemented with 20 mM Hepes，2 mM of glutamine and 0.024 mg/ml gentamycin (all 
from GIBCOBRL). The cells were maintained under a fully humidified atmosphere with 
5% CO2 at 37°C in 25 cm^ sterile polystyrene tissue culture flasks. All cultures were 
routinely passaged three times a week. 
2.2.2 Cytotoxic and Cytostatic Effects on the Cancer Cells 
CHL used in this study was purchased from Sigma. Stock solution of 10 mg/ml CHL 
in ultrapure water was prepared immediately before use, and serial dilutions were 
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performed in the cell culture media just before addition to the cells. Different cancer cells 
were seeded in 96-well flat bottom culture plates at an initial density 2.5 x 10^ cells per 
100 \x\ (i.e. 2.5 x cells/ml). The cells were allowed to grow for 24 h for 
acclimatization. The cells were then incubated with 0，25，50, 100，200 and 400 |ig/ml of 
CHL for 72 h, respectively. Different assays were then applied to examine the effects of 
CHL on controlling the cancer cell growth. 
a. MTT Assay 
The cytotoxic effects of CHL on MCF-7, HeLa, HepG2 and HEp-2 cells were 
determined by MTT assay (Mosmann, 1983). MTT solution was freshly prepared by 
dissolving MTT (3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) 
in filtered PBS at 5 mg/ml. After 72 h of incubation, 10 |il of the MTT solution were 
added to each well. After 5 h of incubation, the medium was removed and the blue 
formazan formed was dissolved by adding 150 \i\ of acidic isopropanol (0.04 N HCl). All 
the wells were then mixed by pipetting until all crystals were dissolved completely. 
Absorbance of the blue formazan solution generated was measured at 570 nm by a 
microplate reader. Percentage of growth inhibition of the cancer cells was expressed by 
the following equation: 
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广 Average absorbance of treatment group � 
1- X 100% 
� Average absorbance of control group 
The concentration-growth inhibition curve was plotted. 
b. Chemiluminescent-Bromodeoxyuridine (Chemi-BrdU) Immunoassay 
Effect of CHL on the proliferation of MCF-7 cells was further determined using the 
Cell Proliferation ELISA，BrdU (Chemiluminescence) Kit (Roche Molecular 
Biochemicals, Mannheim, Germany). After the CHL incubation, 10 \i\ BrdU labeling 
solution (provided) was added to each well and incubated at 37°C for 2 h. After 
centrifugation at 300 g for 10 min, the supernatant was removed, and the plate was 
aspirated for 15 min. Two hundred microliters of Fix-Denat solution (provided) were 
added to each well to fix the cells, and the plate was allowed to stand for 30 min at room 
temperature. After removing the Fix-Denat solution, the diluted anti-BrdU-POD working 
solution (provided) was added to each well and incubated for 90 min. After rinsing three 
times with the provided washing buffer，100 |il substrate solution was added and allowed 
to react for 3 min with shaking at room temperature. The luminescence emitted from the 
wells was determined with a microplate luminometer with photomultiplier technology. 




广 Average luminescence of treatment g r o u p � 
1- X 1 0 0 % 
� Average luminescence of control group ^ 
The concentration-proliferation inhibition curve was plotted so that the concentration of 
CHL with 50% inhibition on the cancer cell proliferation ( IC50) could be estimated. 
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2.2.3 DNA-Flow Cytometric Analysis 
Effects of CHL on the cell-cycle distribution and apoptosis induction in the breast 
carcinoma MCF-7 cells were analyzed by Beckman Coulter Epics XL.MCL flow 
cytometer (Miami, FL). The breast cancer cells were seeded in 25 cm^ sterile polystyrene 
tissue culture flasks at density 2.5 x cells/ml. After 24 h of incubation for 
acclimatization, the cells were incubated in the absence or presence of 123.5 |ig/ml (i.e. 
IC50) of CHL for 24, 48，72 and 96 h，respectively. After the different periods of 
incubation, 1 x 10^ MCF-7 cells were harvested and washed twice with PBS and 
centrifuged at 514 g for 5 min. The cells were then fixed in 70% ethanol at -20°C 
overnight. The fixed cells were washed twice with PBS and then incubated in dark for 30 
min with 1 ml PBS solution, containing 1 mg/ml ribonuclease and 10 ^ig/ml PI (all from 
Sigma). Finally, the stained cells were analyzed by flow cytometer. The red fluorescence 
from PI was measured at >625 run. Cell-cycle distribution was analyzed using MultiCycle 
software (Phoenix Flow Systems, San Diego, CA). 
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2.2.4 Western Blot Analysis 
Effects of CHL on some specific protein expressions were identified and 
semi-quantified in the MCF-7 cells by Western blot analysis. The cancer cells were first 
seeded in 25 cm^ sterile polystyrene tissue culture flasks at density 2.5 x cells/ml. 
After 24 h of incubation for acclimatization, the cells were incubated in the absence or 
presence of 123.5 |xg/ml (i.e. IC50) of CHL for 24, 48, 72 and 96 h, respectively. After the 
different periods of incubation, cell lysate was prepared from 2 x 10^ MCF-7 cells 
(detailed in Section 2.2.4 a). Proteins in the cell lysate were measured using BCA assay 
(detailed in Section 2.2.4 b). Protein denaturation was then carried out (detailed in Section 
2.2.4 c) and 30-100 fxg of the total cell lysate proteins were resolved by 13% 
SDS-polyacrylamide gel. The resolved proteins were then transferred to a Hybond^^-C 
nitrocellulose membrane (Amersham Life Science, Buckinghamshire), which was then 
blocked with 0.2% Aurora® blocking reagent (ICN Biomedicals, OH) or 0.5% non-fat dry 
milk with 0.1% Tween 20 solution (Bio-Rad Laboratories, Hercules, CA). The blocked 
membrane was then incubated with the mouse anti-human primary antibody overnight 
with shaking at 4°C. The primary antibodies used in this study included Bcl-2 (clone 7) 
and Cyclin D1 (clone GI24-326) (both from BD Biosciences PharMingen, San Jose, CA); 
Bad, BC1-XL, c-Jun, phospho-c-Jun (Ser63) II, SAPK/JNK, phospho-SAPK/JNK 
(Thrl83/Tyrl85) (clone G9) and PARP (all from Cell Signaling Technology, Beverly, 
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MA); and p-actin (Sigma). After the incubation, the membrane was then washed and 
incubated with horse-radish peroxidase-conjugated goat anti-mouse IgG polyclonal 
antibodies (Cell Signaling Technology) for 1 h at room temperature. The protein bands on 
the membrane were then visualized with the chemiluminescent substrate (Cell Signaling 
Technology) by exposing to X-ray films. 
a. Cell Extract Preparation 
After the different periods of incubation with CHL, 2 x 10^ cells were harvested for 
cell extraction. The cells were washed twice with ice-cold PBS and centrifuged at 514 g 
for 5 min at 4°C. The cell pellet was then resuspended and homogenized in 49 \i\ lysis 
buffer with 1 |LI1 protease inhibitor (PharMingen). The cell lysate was then transferred to a 
microcentrifuge tube and incubated on ice for 45 min. After the incubation, the cell lysate 
was centrifuged at 17746 容 for 15 min at 4°C. Finally, the supernatant containing both the 
soluble transmembrane and cytosolic proteins were collected and freezed at -20°C. 
b. Bicinchoninic Acid (BCA) Assay 
After the cell extraction, the protein content was measured using the BCA assay 
(Pierce Chemical Company, Rockford). Standard curve was prepared with 0，25, 50, 100, 
200 and 400 fig/ml of bovine serum albumin per 50 |il in microcentrifuge tubes for 
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calibration. On the other hand, 1 |il of total cell lysates was diluted with 49 [x\ ultrapure 
water for protein content measurement. One milliliter of working reagent (provided) was 
then added to each microcentrifuge tube and incubated for 30 min at 37�C. After the 
incubation, the tube was cooled to room temperature and the absorbance was measured at 
562 nm by Eppendorf BioPhotometer (Hamburg, Germany). 
c. Protein Denaturation 
After the protein measurement, equal amount of proteins from each sample was 
denatured. Loading buffer, containing 4% SDS and 2% 2-mercaptoethanol to denature 
and dissociate the proteins into rodlike shape with evenly distributed negative charge for 
SDS-PAGE, and 10% glycerol to prevent the sample from mixing with the buffer, was 
prepared. Equal amount and volume of proteins from each sample was mixed with the 
loading buffer in the ratio of 1 to 1 in microcentrifuge tube. After vortexing, the tubes 
were incubated for 5 min at 95°C • 
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2.2.5 JC-1 Mitochondrial Potential Sensor 
Effect of CHL on the mitochondrial membrane potential of MCF-7 cells was 
analyzed by flow cytometer, with the application of 
5,5 ',6,6'-tetrachloro-1,1' ,3,3 '-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) 
(Invitrogen Molecular Probes™, Carlsbad, CA). JC-1 is a cationic dye that exhibits 
potential-dependent accumulation in mitochondria, indicated by a fluorescence emission 
shift from red (-590 nm) to green (-525 nm). Consequently, mitochondrial depolarization 
is indicated by a decrease in the red/green fluorescence intensity ratio. The 
potential-sensitive color shift is due to concentration-dependent formation of red 
fluorescent J-aggregates. MCF-7 cells were seeded in 25 cm^ sterile polystyrene tissue 
culture flasks at density 2.5 x lO^ cells/ml. After 24 h of incubation for acclimatization, 
the cells were incubated in the absence or presence of 123.5 ^ig/ml (i.e. IC50) of CHL for 
24, 48 and 72 h, respectively. One million cells were then harvested and the dissociated 
cells were stained by 10 |ig/ml of JC-1 at 37°C for 10 min. The stained cells were then 
washed once and resuspended with PBS and analyzed by Beckman Coulter Epics 
XL-MCL flow cytometer. The red fluorescence from JC-1 aggregates was measured at 
590 nm 士 17.5 nm and the green fluorescence from JC-1 monomers was measured at 530 
nm 士 15 nm. 
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2.2.6 Caspase Inhibitors 
The involvement of caspases in the CHL-induced apoptosis was investigated using 
DNA-flow cytometer to measure the DNA fragmentation, with the applications of general 
caspase (Z-VAD-FMK), caspase-6 (Ac-VEID-CHO) and caspase-9 (Z-LEHD-FMK) 
inhibitors (all from PharMingen). MCF-7 cells were seeded in 25 cm^ sterile polystyrene 
tissue culture flasks at density 2.5 x lO^ cells/ml. After 24 h of incubation for 
acclimatization, the cells were preincubated in the presence of 20 |iM general caspase, 
caspase-6 or caspase-9 inhibitor for 30 min followed by the CHL treatment. 0.2% DMSO 
was added to the control and the CHL-treated-only cells. After 72 h of incubation, 1 x 10^ 
cells were then harvested and washed twice with ice-cold PBS. Finally, the cells were 
fixed with 70% ethanol and freezed at -20°C overnight. The DNA-flow cytometric 




2.2.7 Statistical Analysis 
Results are expressed as mean 土 standard deviation (S.D.). Difference in means 
between the control and treatment groups was compared by either Student's 广test, p<0.05 
or one-way ANOVA followed by Tukey's test for multiple comparisons, p<0.05. 
2.2.8 Densitometric Analysis 
Densitometric measurement of immunoblots was performed using LumiAnalyst 3.1 




2.3.1 Effects of CHL on the Growth of Human Cancer Cells by MTT Assay 
MTT assay was applied to study the cytotoxic effects of CHL on MCF-7, HeLa, 
HepG2 and HEp-2 cells. CHL reduced the growth of the cancer cells in a dose-dependent 
manner. At the highest concentration of 400 |ig/ml after 72 h of incubation, CHL reduced 
the growth of MCF-7, HeLa, HepG2 and HEp-2 cells by 92.5%, 77.4%，65.1% and 
74.5% respectively, when compared to their control levels (Fig. 2.2). 
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Fig. 2.2 Effects of CHL on the Growth of MCF-7, HeLa, HepG2 and HEp-2 
Cells. 
The cells were incubated with 25, 50，100’ 200 and 400 ng/ml of CHL 
respectively for 72 h and measured by MTT assay. Results are expressed 
as mean 士 S.D. of three independent experiments. Difference in means 
between the control and treatment groups was compared by Student's 
t-test, *p<0.05; **p<0.01; and ***p<0.001. CHL reduced the growth of 
the cancer cells in a dose-dependent maimer, with the maximum 




2.3.2 Effect of CHL on the Proliferation of MCF-7 Cells by Chemi-BrdU Incorporation 
To investigate the cytostatic effect of CHL on the breast cancer MCF-7 cells, the 
level of BrdU incorporation was used to indicate the extent of the cell proliferation under 
the influence of CHL. As BrdU is an analogue of pyrimidine, which incorporates into the 
DNA of proliferating cells, the level of BrdU incorporation represents the proliferative 
potential of the cancer cells. After 72 h of incubation with increasing concentrations of 
CHL, a dose-dependent decrease in the incorporation of BrdU, i.e. the proliferative 
potential of the breast cancer cells, by 18.5 to 95.5% of the control level was observed 
(Fig. 2.3). The IC50 was estimated as 123.5 fxg/ml. 
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Fig. 2.3 Effect of CHL on the Proliferation of MCF-7 Cells. 
The cells were incubated with 25, 50, 100，200 and 400 |ng/ml of CHL 
respectively for 72 h and measured by chemi-BrdU assay. Results are 
expressed as mean 土 S.D. (n=4). Difference in means between the control 
and treatment groups was compared by Student's Mest，*p<0.05; 
**p<0.01; and ***p<0.001. CHL reduced the proliferation of the breast 




2.3.3 Effect of CHL on Cell Cycle of MCF-7 Cells 
CHL reduced the proliferation of MCF-7 cells by 50% at 123.5 |ig/ml after 72 h of 
incubation (Fig. 2.3). By comparing the proportion of cells in the different phases of cell 
cycle, the effect of CHL on the cell-cycle progression in the breast cancer cells was 
elucidated. The cancer cells were treated with the IC50 of CHL for the different periods 
(Fig. 2.4). At 24 h of incubation, CHL increased GQ/GI cells from the control 3 8 . 7 % of 
the cells in cell cycle to 44.9%; the S cells, on the other hand, reduced from the control 
44.2 to 37.9% after the treatment. At 48 h of incubation, CHL accumulated the G2/M cells 
from 14.7% in the control cells to 2 1 . 9 % , with concomitant decrease of the GQ/GI cells 
from 52.9 to 47.7%. The Gz/M-arrest persisted at 72 and 96 h, so that the cells elevated 



























































































































































































































































































































































































































































































































































































































































































2.3.4 Effect of CHL on the Cyclin Dl Expression in MCF-7 Cells 
Cyclin Dl is an important regulator of the breast cancer cell proliferation (Bartkova 
et al., 1994; Gillett et al, 1994). As shown in Fig. 2.6 (a), Cyclin Dl was started to be 
downregulated at 24 h of incubation with the IC50 of CHL. The CHL-induced Cyclin Dl 
downregulation was time-dependent so that the Cyclin Dl expression was completely 











































































































































































































































































































2.3.5 Effects of CHL on JNK and c-Jun Expressions and Their Phosphorylations in 
MCF-7 Cells 
JNK constitutes a subfamily of MAPKs and plays a critical role in coordinating the 
cellular response to stress (Xia et al., 1995; Davis, 2000); it has been implicated in 
regulating cell growth (Lopez-Ilasaca et al., 1997; Antonyak et al, 1998) and 
transformation (Behrens et al., 1999; Wisdom et al., 1999). c-Jun is a substrate of JNKs, 
and the phosphorylated c-Jun (p-c-Jun) forms AP-1 to regulate the expressions of other 
genes such as Cyclin Dl , driving the cell-cycle progression (Derijard et al,, 1994; 
Rennefahrt et al” 2005). As shown in Fig. 2.7 (a), level of the phosphorylated JNK 
(p-JNK) was reduced after the different periods of incubation with CHL, indicating that 
the JNK activation was lowered after the CHL treatment. Although JNKs were strongly 
deactivated, levels of the total JNKs, i.e. both the phosphorylated and unphosphorylated 
forms, were not significantly affected by CHL after the different periods of incubation 
[Fig. 2.7 (b)]. In meanwhile, CHL also lowered the level of c-Jun phosphorylation 
time-dependently, indicating that the CHL treatments reduced the activation of c-Jun [Fig. 
2.7 (c)]. The level of total c-Jun, i.e. both the phosphorylated and unphosphorylated forms, 
on the other hand, remained unchanged with the different periods of CHL incubation, 































































































































































































































































































































































































































































































2.3.6 Effect of CHL on DNA fragmentation in MCF-7 Cells 
In addition to cell-cycle modulation, the effect of CHL on apoptosis induction, which 
is an important cancer therapeutic strategy, was also investigated. According to the results 
from DNA-flow cytometry, in addition to cell-cycle modulation, CHL also induced DNA 
fragmentation, which is a characteristic feature of apoptosis, in the breast cancer cells 
early at 48 h of incubation. The percentage of apoptotic cells increased time-dependently 
from 4-fold at 48 h to 40-fold at 96 h of incubation comparing to the control levels (Fig. 
2.4 & 2.8). 
78 
Chapter 2 












1 2 0 - r 
1 - … ^ 
0 " t a C Z f Z D I T I J I m ^ m J 1 ^ 1 
^ 24 48 72 96 
Time (h) 
Fig. 2.8 Numeric Data Showing the Effect of CHL on DNA Fragmentation 
in MCF-7 Cells. 
The cells were incubated with the ICsoofCHL ( • ) or without CHL ( • ) 
for 24, 48，72 and 96 h respectively and measured by flow cytometer. 
Results are expressed as mean 士 S.D. (n=3). Difference in means 
between the control and treatment groups was compared by Student's 
Mest’ ***p<0.001. CHL induced DNA fragmentation early at 48 h and 
the increase occurred in a time-dependent fashion. 
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2.3.7 Effect of CHL on Mitochondrial Membrane Potential of MCF-7 Cells 
Mitochondrial membrane depolarization, which occurs in the earlier stage of 
apoptosis, can be detected when the mitochondria permeability transition pores open 
resulting in the free distribution of ions between both sides of the membrane (Gross et al., 
1999). Since the DNA fragmentation induced by CHL was observed after 48 h of 
incubation (Fig. 2,8), which is a phenomenon that occurs in the later stage of apoptosis, 
the mitochondrial membrane potential was then investigated with the application of JC-1 
in order to confirm the effect of CHL on apoptosis induction. As shown in Fig. 2.9, effect 
of CHL on the mitochondrial membrane potential was determined after 24，48 and 72 h of 
incubation, respectively. Under normal circumstances, JC-1 accumulates in active 
mitochondria in which it oligomerizes and fluoresces red. A reduction in mitochondrial 
membrane potential results in the replacement of red JC-1 aggregates by green JC-1 
monomers and a subsequent increase in the mean green fluorescent intensity. As expected, 
control cells showed a low mean green fluorescence after staining with JC-1, indicated by 
the blue rectangles in Fig. 2.9 (a), (b) and (c). Treatment with CHL induced a shift of cell 
population to the right early at 24 h of incubation, comparing to the control [Fig. 2.9 (d)]. 
This implied that CHL induced depolarization of mitochondrial membrane potential 
preceding the DNA fragmentation. In meanwhile, the mean red fluorescence gradually 
decreased from 24 to 72 h of incubation with CHL so that the red fluorescence dropped 
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prominently at 72 h [Fig. 2.9 (d), (e) & (f)]，implying that there was a complete collapse 
of the mitochondrial membrane potential so that the mitochondria were no longer 








































































































































































































































































































































































































































































2.3.8 Effects of CHL on the PARP Expression and Cleavage in MCF-7 Cells 
PARP is a nuclear enzyme involved in several cellular functions, including DNA 
repair, DNA transcription and apoptosis (D'Amours et al., 1999; Scovassi and Poirier， 
1999; Ziegler and Oei，2001). Interestingly, CHL elevated the expression of PARP early at 
24 h of incubation and the elevation occurred in a time-dependent fashion. 
Simultaneously, the PARP was cleaved after 24 h of treatment with CHL so that all the 





































































































































































































































































































































































2.3.9 Effects of CHL on Bcl-2, BC1-XL and Bad Expressions in MCF-7 Cells 
At 24 h of incubation with CHL, mitochondrial membrane depolarization in the 
breast cancer cells was detected (Fig. 2.9). The mitochondrial release of proapoptotic 
molecules is the main signaling pathway leading to cell death, which is under the control 
of the Bcl-2 family proteins (Strasser et al., 2000; Adams and Cory, 2001). Therefore, the 
expressions of some of the Bcl-2 family proteins were measured in the breast cancer cells 
after the C H L treatment. It is recognized that both Bcl-2 and BCI-XL inhibit the release of 
cytochrome c and other mitochondrial membrane events during apoptosis (Budihardjo et 
al., 1999; Daniel et al., 2003). Thus, the expression of these two antiapoptotic proteins 
after the CHL treatment was first investigated. CHL appeared to reduce the Bcl-2 
expression after 72 and 96 h of incubation [Fig. 2.11 (a) & Table 2.1]. On the contrary, the 
expression of BC1-XL protein remained constant after the different periods of incubation 
[Fig. 2.11 (b)]. Besides studying the antiapoptotic proteins, the proapoptotic Bad protein 
was also examined. Bad is a proapoptotic member of the Bcl-2 family that can displace 
Bax-like proteins from binding to Bcl-2 and BC1-XL, resulting in cell death (Daniel et al, 
2003). As shown in Fig. 2.11 (c)，the expression of Bad protein remained constant after 




































































































































































































































































































































































































































































































































































































































































































































2.3.10 Effects of CHL on Caspase Activations in MCF-7 Cells 
Procaspase-6, -7, -8 and -9 were expressed in MCF-7 cells. At 72 h of incubation 
with CHL, levels of procaspse-7 and -8 were not different from their control levels [Fig. 
2.12 (b) & (c)]. On the other hand, levels of procaspase-6 and -9 were decreased after the 
CHL treatment [Fig. 2.12 (a) & (d)], suggesting that the caspases might be cleaved and 
activated during the cell-death process. 
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(a) ^f^rnm 衡 35 Procaspase-6 
(b) mtm^ 35 Procaspase-7 
(c) .权’ W K M 57 Procaspase-8 
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Fig. 2.12 Immunoblots Showing Effects of CHL on Caspase Activations in 
MCF-7 Cells. 
The cells were incubated with the IC50 of CHL for 72 h. The expression 
of p-actin was used as internal control to normalize the expressions of 
other proteins. One representative experiment of two is shown. CHL 
reduced the levels of procaspase-6 and caspase-9 while the levels of 
procaspse-7 and -8 were not different from their control levels. 
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2.3.11 Effects of Caspase Inhibitors on the CHL-induced Apoptosis in MCF-7 Cells 
By pretreating the breast cancer cells with selective caspase inhibitors followed by 
72 h of incubation with the IC50 of CHL and by comparing the proportion of cells with 
fragmented DNA in DNA-flow cytometry, the roles of different caspases in the 
CHL-induced apoptosis were elucidated. Results from the DNA-flow cytometry showed 
that CHL elevated the apoptotic cells prominently after 72 h of incubation (Fig. 2.13)， 
which was accompanied by the decreases and probably the fragmentation of procaspase-6 
and -9 but not procaspase-7 and -8. To further confirm whether the CHL-induced 
apoptosis involves cleavage and thus activations of caspase-6 and -9, specific caspase-6 
and caspase-9 inhibitors were used to see if they could impair the CHL-induced apoptosis. 
The general caspase inhibitor was also applied to examine if the CHL-induced apoptosis 
was only caspase-dependent. The general caspase, caspase-6 and caspase-9 inhibitors 
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Fig. 2.14 Numeric Data Showing Effects of Different Caspase Inhibitors on the 
CHL-Induced Apoptosis in MCF-7 Cells. 
Results are expressed as mean 土 S.D. (n=3). The bars marked by the same 
letter have no significant difference. Difference in means between the 
control and treatment groups was compared by one-way ANOVA followed 
by Tukey's test for multiple comparisons, p<0.05. The general caspase, 
caspase-6 and caspase-9 inhibitors significantly reduced the CHL-induced 




At the beginning of the in vitro study, four different cancer cell lines, including 
human breast carcinoma MCF-7, cervical carcinoma HeLa, hepatocellular carcinoma 
HepG2 and laryngeal carcinoma HEp-2, were used for the preliminary screening of the 
growth inhibitory effects of CHL. MTT assay, which is an economical and rapid method 
for measuring cell proliferation and cell death in terms of the level of cellular metabolic 
activity, was first applied to study the cytotoxic effects of the different doses of CHL on 
the cancer cells. CHL exhibited cytotoxic effects on MCF-7, HeLa, HepG2 and HEp-2 
cancer cells dose-dependently. At the highest concentration of 400 jLig/ml of CHL after 72 
h of incubation, the percentage of growth inhibition was determined for the different 
cancer cells, ranging from 65.1 to 92.5% of their control levels. By comparing the 
percentage of maximum growth inhibition, MCF-7 was found to be most responsive to 
the CHL treatment. The mechanistic actions for the cytotoxic effect of CHL on MCF-7 
cells were further elucidated in this study. 
Cell growth is a balance between cell proliferation and cell death. To investigate the 
MCF-7 cell proliferation, the level of BrdU incorporation in the breast cancer cells was 
measured after incubation with different concentrations of CHL. Since BrdU is an 
analogue of pyrimidine and its incorporation level into the cellular DNA is a measure of 
proliferation, the decrease in BrdU incorporation after the CHL treatment implied that 
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CHL had retarded the MCF-7 cell proliferation. Diaz et al (2003) reported previously 
that CHL inhibited the growth of human colon cancer HCT116 cells. Results from this 
study also suggested that CHL suppressed the aberrant cell proliferation in vitro. Since the 
breast carcinoma MCF-7 was the most responsive cell line to the CHL treatment, the 
molecular mechanisms for the growth inhibition were further investigated. 
Cell cycle proceeds by ways of well-defined successive steps, each of which must be 
completed before the beginning of the next. There are four serial biologically defined 
phases: Gi (first gap), S (DNA synthesis), G2 (second gap), and M (mitosis). CHL, after 
24 h of incubation at concentration 123.5 |j.g/ml, accumulated the breast cancer cells at 
the Gi phase. After 48 h of incubation with CHL, the G2/M cells were elevated with a 
significant increase of the apoptotic cells. The G2/M arrest, as well as the apoptosis 
induction, was persisted at 72 and 96 h of incubation with CHL. It seemed that the effects 
of CHL on cell cycle depended on the periods of treatment and were biphasic in the breast 
cancer cells. The prolonged arrest at G2/M phase might induce some of the arrested cells 
to undergo apoptosis with the associated DNA fragmentation. Choi et al. (2001) found 
that quercetin, a widely distributed bioflavonoid, also induced growth inhibition on 
MCF-7 cells by accumulating the cells specifically at G2/M phase of the cell cycle. The 





Cell-cycle progression through different phases and checkpoints is tightly regulated 
by different cyclins and their dependent kinases (Cdks). The D-type cyclins specify the 
family of three closely related proteins (cyclins Dl, D2 and D3), which operate during the 
Gi phase by binding to and activating Cdk4 or Cdk6, and phosphorylating the 
retinoblastoma tumor suppressor gene product (pRb) (Pines et al., 1995; Morgan, 1997; 
Sherr and Roberts, 1999). This phosphorylation leads to release of pRb-bound 
transcription factors, notably the E2F family of transactivators, and to de-repression or 
activation of E2F-controlled genes, such as cyclin E (Ohtani et al., 1995; Schulze et al., 
1995). In this study, CHL downregulated the expression of Cyclin Dl early at 24 h of 
incubation with concomitant increase of the Gi cells, which seemed to account for the 
antiproliferative effect during the early phase of the CHL treatment. The reduction of the 
Cyclin Dl expression was in a time-dependent manner; however, no concomitant 
accumulation of the Gi cells was observed with longer periods of treatment. Instead, 
G2/M cells were accumulated and apoptosis was induced during the later phase of the 
CHL treatment, suggesting that different signaling cascades were integrated to control the 
cancer cell growth. 
JNK is a member of a subfamily of MAPKs, which plays a critical role in 
coordinating the cellular response to stress (Xia et al” 1995; Davis, 2000) and has been 
implicated in regulating cell growth (Lopez-Ilasaca et al.’ 1997; Antonyak et al, 1998) 
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and transformation (Behrens et al, 1999; Wisdom et al., 1999). JNK substrates such as 
ATF-2, c-Jun, Bcl-2, BC1-XL, P2LCIP"WAFL，肌d p53 have been identified and have provided 
insight into the ultimate effect(s) of activated JNK within varying cellular contexts 
(Maundrell et al, 1997; Yamamoto et al” 1997; Davis, 2000). Cyclin D1 can be induced 
by the ectopic expression of c-Jun (Albanese et al, 1995)，which is JNK's most-studied 
substrate, and it alone leads to complex responses to regulates genes such as cyclin Dl, 
p53, p21 Cipi/wafi，P19ARF’ and pi6, which affect cell proliferation and apoptosis (Jochum 
et al, 2001; Shaulian and Karin, 2001; Vogt, 2001). Compatible to the decrease in Cyclin 
Dl , p-c-Jun was also decreased time-dependently after the CHL treatment. In addition, 
the upstream signaling mediator of c-Jun, the phosphorylated JNK (p-JNK), was reduced 
after the different periods of incubation with CHL. Young et al (2005) showed that 
MCF-7 cells stably transfected with RASSFIA, a putative tumor suppressor gene, 
inhibited cell-cycle progression with suppression of JNK phosphorylation, c-Jun 
phosphorylation and Cyclin Dl downregulation. Results from the present study suggest 
that the CHL-induced downregulation of Cyclin Dl may also be mediated by the 
deactivation of JNK. Mingo-Sion et al (2004) also showed that, besides controlling cell 
growth, basal JNK activity is required for the survival of MCF-7 cells and inhibition of 
JNK activity causes G2/M arrest and apoptosis. As shown in this study, the activated JNK 
was continuously depleted by the CHL treatment, with accumulation of G2/M cells and 
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apoptosis induction during the later phase of treatment. All these findings suggested that 
depletion of the basal JNK activity by the CHL not only deactivated c-Jun and might thus 
lead to Cyclin Dl downregulation but also somehow caused G2/M arrest and apoptosis in 
the breast cancer cells. 
There are two different modes of cell death which are necrosis and apoptosis. 
Necrosis is a passive process which happens as a result of physical or chemical injury. In 
contrast, apoptosis is an active process which occurs in response to specific stimulations 
and is tightly regulated by genes inducing cell death. In comparison to necrosis, which is 
a broad spectral process, the involvement of apoptosis during cancer therapy is 
particularly important since it involves a series of genetic processes which might be 
triggered specifically in certain cell types (Kerr et al., 1994; Anderson et al, 1995; Benito 
et al” 1997). This characteristic feature of apoptosis has attracted intensive investigations 
in its significance during the anticancer drug development (Kerr et al, 1994; 
Darzynkiewicz, 1995a; Ohizumi et al., 1997). Apoptosis is characterized as a 
well-ordered, programmed sequence of events for cell death, in which the loss of 
mitochondrial membrane potential through the action of the Bcl-2 family of proteins, 
caspase activation, and DNA fragmentation are the hallmarks (Gilmore et al, 2000). The 
apoptotic DNA fragmentation at the intemucleosomal linker regions of genomic DNA 
produces fragments of sizes which are multiples of nucleosomes，and will appear as 
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discrete apoptotic peak on the left of Gi peak in histogram of DNA-flow cytometry 
(McConkey et al, 1996; Tanuma and Shiokawa, 1996). Although DNA fragmentation can 
also occur in the necrotic cells, unlike that of apoptosis, the genomic DNA of necrotic 
cells is degraded randomly into small fragments of variable sizes due to karyolysis 
(Majno and Joris, 1995; Darzynkiewicz et aL, 1997). In this study, exposure of the human 
breast carcinoma MCF-7 cells to CHL caused DNA fragmentation early at 48 h of 
incubation. Since CHL treatment showed an increase in the number of cells with 
fragmented DNA, a mitochondrion-specific probe (JC-1), which accumulates and 
fluoresces red in active mitochondria and becomes green in depolarized mitochondria, 
was used to determine if DNA fragmentation preceded by an alteration of mitochondrial 
function in the CHL-treated cells. It is well known that several stimuli induce a decrease 
in the mitochondrial membrane potential, and this precedes nuclear fragmentation in 
apoptosis (Castedo et al., 1996). In the present study, JC-1 staining of the mitochondria 
detected the depolarization of mitochondrial membrane early at 24 h of incubation with 
CHL. These findings indicated that CHL caused mitochondrial dysfunction and hence 
triggered cell death by apoptosis with ultimate DNA fragmentation. These findings also 
agreed with an earlier report that CHL induced apoptosis with attenuation of the 




During apoptotic cell death, PARP plays two opposite roles in which its stimulation 
leads to poly(ADP-ribose) synthesis, whereas caspase activation causes PARP cleavage 
and inactivation (Kaufmann et al, 1993; Donzelli et al, 1997; Rosenthal et al,, 1997). 
The immunoblot studies revealed that CHL stimulated the expression of full-length PARP 
as well as the cleavage of PARP in the breast cancer cells. The stimulation of PARP in 
apoptotic cells leads to the poly(ADP-ribose) synthesis, which plays a crucial role in 
DNA repair and represents a cellular emergency reaction (D'Amours et al” 1999; 
Scovassi and Poirier, 1999; Ziegler and Oei, 2001). CHL increased the expression of 
PARP early at 24 h of incubation. It is likely that CHL might somehow induce DNA 
damage in MCF-7 cells so that PARP expression was induced for the DNA repair. PARP 
is important for cells to maintain their viability; cleavage of PARP by caspases facilitates 
cellular disassembly and serves as a marker of cells undergoing apoptosis (Kaufmann et 
al.’ 1993). It seemed that the CHL-induced DNA damage could not be repaired so that the 
PARP cleavage began early at 24 h and elevated time-dependently with the CHL 
treatment. These suggested that CHL not only induced apoptosis in the breast carcinoma 
MCF-7 cells but the apoptosis was also caspase-dependent. 
In fact, cell survival depends on the maintenance of mitochondrial membrane 
potential because of its involvement in ATP synthesis and maintenance of oxidative 
phosphorylation (Bolt et al., 2001; Mingatto et al, 2002). We observed that the exposure 
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to CHL resulted in a loss of mitochondrial membrane potential in the breast cancer cells 
starting from 24 h of incubation, which was commensurate with the cleavage of PARP. 
Besides acting as some of the remarkable features of apoptosis, their occurrence also 
suggested the involvement of mitochondria and caspases in the CHL-induced apoptosis. 
The Bcl-2 family proteins, which can be envisioned as general regulators of 
mitochondrial physiology, were then examined in this study to evaluate how CHL caused 
mitochondrial dysfunction and triggered apoptosis in the breast cancer cells with ultimate 
DNA fragmentation. Bcl-2 protein, which is localized on the mitochondrial membrane, 
inhibits the release of apoptogenic factors from mitochondria by several different 
mechanisms, including inhibition of proapoptotic Bax translocation from the cytoplasm to 
mitochondria and trapping of activated proapoptotic Bcl-2 family proteins (Bomer, 2003). 
This would promote apoptosis as a result of a decrease in the free homodimeric form of 
Bcl-2 and an increase in the free homodimeric form of the proapoptotic Bax-like proteins. 
Bcl-2 downregulation was associated with loss of mitochondrial membrane potential, 
reactive oxygen species generation and apoptosis (An et al., 2004). Mandal and Kumar 
(1996) also showed that downregulation of Bcl-2 mRNA and protein levels was in 
connection with the induction of apoptosis in MCF-7 cells by sodium butyrate. In the 
present study, CHL appeared to downregulate Bcl-2 expression, starting from 72 h of 
incubation. In meanwhile, no significant alteration of BC1-XL and Bad proteins was 
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observed. The Bcl-2 expression was only depleted after 72 h of incubation with CHL but 
mitochondrial membrane depolarization was first observed at 24 h, followed by the 
prominent elevation of DNA fragmentation at 48 h. It was found in this study that 
although mitochondrial dysfunction plays a central role in the CHL-induced apoptosis in 
MCF-7 cells, Bcl-2 involves only in the exacerbation rather than the initiation phase of 
the cell death process. Although Bcl-2 does not participate in the initiation phase of the 
cell death process, other antiapoptotic and proapoptotic members of the Bcl-2 family 
might trigger the apoptosis that had not been investigated in this study. Furthermore, 
Halestrap et al (2002) postulated that, instead of modulating the Bcl-2 family proteins, 
some agents can somehow oxidize the critical thiol groups in mitochondrial membrane 
proteins to induce Bax/Bcl-2-indpendent mitochondrial membrane potential collapse and 
discharge of apoptogenic molecules from mitochondria. Further studies are needed to 
determine if CHL induces this alternative route of apoptosis in MCF-7 cells，which is 
independent of the Bcl-2 family proteins. 
Apoptosis induced by different stimuli, such as death ligands, chemotherapeutic 
drugs, or ionizing irradiation, leads to the activation of caspases (Nicholson, 1999). Our 
previous investigation demonstrated that CHL induced cleavage of PARP, which is an 
indication of caspase activation. Caspase-9 and -8 are the initiator caspases of the 
mitochondrial and death receptor apoptotic pathways respectively and caspase-6 and -7 
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are the effector caspases (Salvesen and Dixit, 1997; Thomberry and Lazebnik，1998). The 
caspase activation involves cleavage of its procaspase. CHL did not affect the levels of 
procaspase-8 and -7，suggesting that the breast cancer cells were not died via the death 
receptor pathway of apoptosis and caspase-7 did not take part in the execution phase of 
the cell death process. On the other hand, levels of procaspase-9 and -6 decreased after 
the CHL treatment, suggesting that the caspases might be cleaved and thus activated 
during the cell death. This further suggested the involvement of the mitochondrial 
pathway in the CHL-induced apoptosis and caspase-6 as the effector caspase. To further 
confirm the participation of caspase-9 and -6 in the CHL-induced apoptosis, their specific 
inhibitors were used to see if they could impair the apoptosis. Our data showed that 
treatment of the MCF-7 cells with selective inhibitors of caspase-6 or caspase-9 before 
exposure to CHL had significant inhibitory effects on the subsequent apoptosis induction, 
as did the treatment with the general caspase inhibitor. However, even the general caspase 
inhibitor could not entirely prevent the CHL-induced apoptosis in the breast cancer cells, 
suggesting that in addition to the caspase-dependent apoptosis, the cell death might be 
mediated by some caspase-independent events. There was no significant difference of the 
extent of apoptosis after the treatment with general caspase inhibitor and caspase-6 
inhibitor, indicating that caspase-6 was the main executioner caspase leading to the 
caspase-dependent apoptosis induced by CHL in the breast cancer cells. In addition, the 
102 
Chapter 4 
inhibition of caspase-9 activity also impaired the CHL-induced apoptosis to a similar 
extent as the inhibition of caspase-6 activity, suggesting the caspase-9 might be the 
initiator caspase activated by the CHL treatment in the breast cancer cells. Caspase-9 
functions as the initiator caspase for mitochondria-dependent apoptosis (Wang et al, 2001; 
Read et al., 2002). The involvement of caspase-9, as well as the lack of death receptor 
involvement in the CHL-induced apoptosis, implies an important role for the 
mitochondria-dependent pathway of apoptosis in the cell death process in MCF-7 cells 
induced by CHL. 
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Chapter 3 In Vivo Studies of the Anticancer Effect of Chlorophyllin 
3.1 Introduction 
In Chapter 2, the in vitro cell growth-inhibitory effect of CHL has been discussed, 
which is resulted, at least in part, from the inhibition of proliferation and induction of 
apoptosis. Before a novel anticancer drug or procedure can be tested on humans, it has to 
be shown as effective in controlling tumor growth in laboratory animals (Singh et al., 
2004). Most animal studies employ a strain of mutant mice whose compromised immune 
system makes it impossible for them to reject foreign cells (called xenografts). This 
mutant mouse has no thymus and therefore no T cells, a class of lymphocytes that 
depends on the thymus to develop. It is said to be nude because it is hairless due to the 
presence two copies of the gene "nu" (for nude). Nude mice have also served in the 
laboratory to gain insights into the immune system, leukemia, solid tumors, AIDS and 
other forms of immune deficiency (Rygaard and Povlsen，1969; Karp, 2003). To 
investigate the anticancer activity of CHL in vivo, nude mice transplanted with the breast 
cancer MCF-7 cells were used as a model in this study. Some of the possible mechanisms 
underlying the CHL-mediated inhibition of tumor growth in vivo were also analyzed. As 
indicated in the in vitro studies, CHL induced downregulation of Cyclin Dl and Bcl-2, 
which might be associated with the decreases of proliferation and viability in the breast 
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cancer cells. Consequently, Cyclin D1 and Bcl-2 expressions in the MCF-7 tumor grown 




3.2 Materials and Methods 
Male nude mice (7-8 weeks) were used in this study. All the mice were supplied by 
the Laboratory Animal Service Centre (LASEC) of the Chinese University of Hong Kong. 
The animals were housed in LASEC under the normal laboratory conditions (21±2°C， 
12/12 h light/dark cycle). They were freely accessible to sterile water, and maintained on 
standard rodent chow. All the mice were allowed to acclimatize for a week before each 
experiment. 
3.2.1 Transplantation of MCF-7 Cells into the Nude Mice and Treatment 
Human breast carcinoma MCF-7 cell line was maintained in vitro, and was passaged 
two to three times a week. The viable cells were counted by hemocytometer and Trypan 
blue exclusion method. After adjusting the cell density to 2.5x10 cells/ml, 0.2 ml of 
MCF-7 cells suspension (i.e. 5x10^ cells/0.2 ml) was inoculated subcutaneously onto the 
back of the anesthetized mice (-17-22 g). Ten days after inoculation, the tumor-bearing 
mice were separated into groups and caged randomly. The tumor-bearing mice in the 
treatment groups were administered with CHL at dosage of 12.5, 25 and 50 mg/kg in 0.1 
ml ultrapure water via intraperitoneal (i.p.) injection for 10 consecutive days. The mice in 
the control group received 0.1 ml ultrapure water only. Twenty-one days after the 
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inoculation, the mice were sacrificed by cervical dislocation. Tumors were enucleated 
and weighed. Proteins were also prepared from the tumors for further investigations. 
3.2.2 Western Blot Analysis 
The procedures were described in Section 2.2.4. The primary antibodies used in this 
study included Cyclin D1 (clone G124-326) and Bcl-2 (clone 7) (both from PharMingen), 
and P-actin (Sigma). 
3.2.3 Statistical Analysis 
Results are expressed as mean 土 standard deviation (S.D.). Difference in means 




3.3.1 In Vivo Antitumor Activity of CHL 
CHL was administered to the MCF-7 solid tumor-bearing nude mice to study its in 
vivo antitumor activity. After 10 consecutive days of administration, CHL reduced the 
tumor weight dose-dependently so that the tumor weight reduced significantly by 58.0 





Fig. 3.1 Effect of Different Doses of CHL on the Growth of MCF-7 Solid l\imor. 
Four groups of the tumor-bearing mice each received 0, 12.5, 25 and 50 
mg/kg of CHL respectively for 10 consecutive days. The solid tumors were 
then enucleated and weighed. Numeric data are shown in Fig. 3.2. One 
representative experiment of three is shown. 
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Fig. 3.2 Effect of CHL on the In Vivo Growth of MCF-7 Solid T\imor in Nude 
Mice. 
Results are expressed as mean (g) 土 S.D. of three independent experiments. 
Difference in means between the control and treatment groups was compared 
by Student's t-test, *p<0.05. CHL reduced the tumor weight dose-dependently 
so that the tumor weight reduced significantly by 58.0 and 66.2% of the 
control level at 25 and 50 mg/kg, respectively. 
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3.3.2 In Vivo Effects of CHL on Cyclin Dl and Bcl-2 Expressions in MCF-7 Solid 
Tumor 
As indicated in the in vitro studies, CHL induced downregulation of Cyclin Dl and 
Bcl-2 expressions in the MCF-7 cells, which were associated with the decreases of 
proliferation and viability in the breast cancer cells. In addition to the weight 
determination, the MCF-7 solid tumors were also examined for Cyclin Dl and Bcl-2 
expressions. As shown in Fig. 3.3 (a) & (b)，50 mg/kg CHL markedly reduced the Cyclin 
Dl and Bcl-2 expressions in the MCF-7 solid tumor. 
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Fig. 3.3 Immunoblots Showing In Vivo Antitumor Effects of CHL on Cyclin 
D1 and Bcl-2 Expressions in MCF-7 Solid Tumor. 
MCF-7 solid tumors were prepared from the mice that had received 0, 
12.5, 25 and 50 mg/kg of CHL respectively for 10 consecutive days. 
The expression of p-actin was used as internal control to normalize the 
expressions of other proteins. One representative experiment of four is 
shown. 50 mg/kg CHL markedly reduced the Cyclin D1 and Bcl-2 




Cancer cell cultures provide a valuable tool for rapid screening of potential 
anticancer agents, as well as for the elucidation of the mechanisms for their activity. Prior 
to clinical trials, however, it is essential that the in vivo efficacy of potential anticancer 
agents has to be determined in a suitable animal model (Singh et al., 2004). In this study, 
the nude mice transplanted with the human breast carcinoma MCF-7 were employed as a 
model to investigate the anticancer activity of CHL in vivo and to elucidate some of the 
possible mechanisms underlying the CHL-mediated inhibition of the tumor growth in 
vivo. 
Results from both the in vitro and in vivo studies supported the application of CHL 
from controlling the growth of the breast cancer cells. The in vivo growth of the tumor 
was significantly retarded after the 10-day administrations of >25 mg/kg. 
Results from the previous in vitro studies illustrated that the CHL-induced inhibition 
of the breast cancer cell growth was associated with the depletion of Cyclin Dl and Bcl-2 
expressions. To further analyze the molecular mechanisms underlying the in vivo 
anticancer activity of CHL, the expressions of Cyclin Dl and Bcl-2 proteins in the 
MCF-7 solid tumor transplanted on the nude mice were studied by Western blot analysis. 
CHL was shown to reduce Cyclin Dl and Bcl-2 expressions in the MCF-7 solid tumors at 
the dose 50 mg/kg. Therefore, results of the in vivo studies correlate well with those of the 
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in vitro studies that the CHL-induced growth inhibition of the MCF-7 cells is at least 
associated with the depletion of Cyclin Dl and Bcl-2 expressions. Interestingly, although 
25 mg/kg CHL also significantly retarded the development of the breast cancer, no 
prominent changes of Cyclin Dl and Bcl-2 were observed at the dose. This implied that 
the in vivo application of CHL might trigger some anticancer mechanisms that have not 
been investigated in the present in vitro studies. Further studies are therefore required to 
study the pharmacokinetics and pharmacodynamics of CHL in the laboratory animals. 
Nevertheless, results from the present in vivo studies provide novel insights into the in 
vivo anticancer mechanisms of CHL at least on the breast cancer MCF-7 cells. 
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Chapter 4 General Discussion 
Cancer is a disease that results from a breakdown in a cell's ability to regulate its 
own division. Cancers or malignant tumors are lethal as they can spread to invade the 
neighboring tissues or even to distant organs away from their places of origin (Becker et 
a l , 2003). Conventional medicine treats cancer along the lines of an infection, i.e. an 
invader to be eliminated. This strategy has led to radical attempts to get rid of the tumor 
through the "cut, bum and poison" technique of surgery, radiation and chemotherapy 
(Aziz et al., 2003). However, these approaches have not been able to control the incidence 
of most of the cancer types and cause damages to the normal cells as well. It is recognized 
that the abnormal biology of cancerous tissue is largely a consequence of an altered 
expression of normal cellular processes, rather than the expression of novel processes 
(Mukhtar and Ahmad, 1999; Aziz et al” 2003). Therefore, there is a need to develop 
mechanism-based approaches for the management of cancer. Treatments of breast cancer 
are typically involved surgery and chemotherapy using drugs, such as tamoxifen, that 
target the estrogen receptor. Although antiestrogen therapy can be effective in treating 
estrogen-dependent tumors, some tumors exhibit intrinsic or acquired resistance to these 
modalities and alternative treatments are needed (Ali and Coombes, 2002). 
In the recent past, chemopreventive phytochemicals present in the diet have received 
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much attention. They are appreciative for cancer chemoprevention as they have little or 
no toxic effects in normal and healthy cells, high efficacy against multiple sites, capability 
of oral consumption, known mechanism of action, low cost and acceptance by human 
population (Aziz et al., 2003; Surh, 2003). Chlorophyll is one of the major constitutes in 
human diet and the water-soluble salts of its derivatives, chlorophyllin (CHL), has been 
suggested to have chemopreventive potentials. CHL has been used in a number of clinical 
situations, including as an oral deodorant (Young and Beregi, 1980), and current FDA 
guidelines allow for ingestion of three 100 mg tablets per day. These doses of CHL have 
proven effective in a preliminary intervention study against aflatoxin Bi exposure in a 
high-risk population (Egner et al, 2001). Besides being reported as an effective blocker 
on carcinogenesis, CHL has also been shown to act directly upon the aberrant human 
colon cancer cells (Diaz et al., 2003). The lack in any known toxicity of CHL and its 
potential chemopreventive properties have urged the understanding of the mechanisms 
responsible for the antiproliferative and cytotoxic activities of CHL to expand its clinical 
uses as cancer chemopreventive agent. 
CHL was shown in the present investigation to inhibit the growth of human cancer 
cells of different histotypes, including breast carcinoma MCF-7, cervical carcinoma HeLa, 
hepatocellular carcinoma HepG2 and laryngeal carcinoma HEp-2 cells. The human breast 
carcinoma MCF-7 was found to be the most responsive cell line to the CHL treatment. 
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Results from this study further demonstrated that CHL suppressed the aberrant breast 
cancer cell proliferation in vitro. Diaz et al. (2003) also reported previously that CHL 
inhibited the growth of human colon cancer HCT116 cells. Since cell growth is a balance 
between cell proliferation and cell death, both these events have to be considered 
simultaneously to understand the anticancer actions of CHL on the MCF-7 cells. 
Responses of the breast cancer cells to the antiproliferative and cytotoxic actions of 
CHL occurred in a dose-dependent manner. DNA-flow cytometry was used to further 
examine the time effects of the IC50 of CHL on both the cell proliferation and cell death. 
Cell cycle proceeds by ways of well-defined successive steps, each of which must be 
completed before the beginning of the next. There are four serial biologically defined 
phases: Gi (first gap), S (DNA synthesis), G2 (second gap), and M (mitosis). DNA-flow 
cytometric data illustrated that the antiproliferative action of CHL was associated with the 
accumulation of cells at GQ/GI phase of the cell cycle at 24 h, followed by the arrestment 
of cells at G2/M phase. The increase of GQ/GI cells during the early phase of treatment 
was likely to prevent the cell-cycle progression, and hence inhibited the cancer cells to 
divide and multiply successfully. Different types of cyclins regulate cell-cycle progression 
through different cell-cycle checkpoints. The D-type cyclins operate during the Gi phase 
(Pines, 1995). In the present study, the semi-quantitative Western blot analysis showed 
that CHL depleted the Cyclin Dl expression early at 24 h of incubation. It is likely that 
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CHL can somehow induce the downregulation of Cyclin D1 expression in the breast 
cancer cells so that its cell-cycle transition through the Gi checkpoint is retarded, leading 
to the cell-cycle arrestment at Gi phase during the early phase of treatment. Interestingly, 
the Cyclin D1 expression was depleted time-dependently with the longer periods of 
treatment with CHL but G2/M arrest, instead of G! arrest, was observed during the later 
phase of treatment, suggesting that different signaling cascades might be integrated to 
control the growth of the breast cancer cells. 
c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), which is a 
subfamily member of the mitogen-activated protein kinases (MAPKs), plays a critical 
role in coordinating the cellular response to stress (Xia et al., 1995; Davis，2000) and has 
been implicated in regulating cell growth (Lopez-Ilasaca et al.’ 1997; Antonyak et al, 
1998) and transformation (Behrens et al., 1999; Wisdom et al, 1999). Cyclin D1 can be 
induced by the ectopic expression of c-Jun (Albanese et al, 1995), which is the JNK's 
most-studied substrate and it alone regulates genes such as cyclin Dl, p53, p21 Cipi/wafl， 
PI9ARF，and pi6, affecting cell proliferation and apoptosis (Jochum et al, 2001; Shaulian 
and Karin, 2001; Vogt, 2001). Compatible to the decrease in Cyclin Dl, p-c-Jun, the 
active form of c-Jun, was also decreased time-dependently with the CHL treatment. In 
addition, p-JNK, the upstream active signaling mediator of c-Jun, was reduced after the 
different periods of incubation with CHL. Young et al. (2005) showed that MCF-7 cells 
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Stably transfected with RASSFIA, a putative tumor suppressor gene, inhibited cell-cycle 
progression with suppression of JNK phosphorylation, c-Jun phosphorylation and Cyclin 
Dl downregulation. Results from the present study suggest that the CHL-induced 
downregulation of Cyclin Dl may also be mediated by the deactivation of JNK so as to 
induce the Gi arrest. Mingo-Sion et al (2004) also showed that，besides controlling cell 
growth, basal JNK activity is required for the survival of MCF-7 cells and inhibition of 
JNK activity causes G2/M arrest and apoptosis. As shown in this study, the activated 
p-JNK was continuously depleted by the CHL treatment, with accumulation of G2/M cells 
and apoptosis induction during the later phase of treatment. All these findings suggested 
that depletion of the basal JNK activity by CHL not only deactivated c-Jun and might thus 
lead to the Cyclin Dl downregulation and Gi arrest but also somehow caused G2/M arrest 
and apoptosis in the breast cancer cells. The activity of a protein depends on the degree 
and duration of phosphorylation, which may be influenced by the activity of two enzyme 
systems, protein kinase and protein phosphatase, working in opposition. Anisomysin and 
okadaic acid are known as an activator of some protein kinases, especially JNK and an 
inhibitor of serine/threonine phosphatases, respectively (Laderoute and Webster, 1997). 
Further investigations to reactivate JNK by direct chemical stimulation using anisomysin 
or inhibition of the dephosphorylation using okadaic acid can provide additional 
information for the cause-and-efFect relationship between the inactivation of JNK and the 
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growth inhibition induced by CHL in the breast cancer cells. 
CHL not only inhibited the proliferation of the breast cancer cells but also induced 
cell death. CHL was also found previously to induce apoptosis with loss of mitochondrial 
membrane potential in human colon cancer HCT116 cells (Diaz et cd” 2003). Apoptosis is 
characterized as a well-ordered, programmed sequence of events for cell death, in which 
loss of mitochondrial membrane potential through the action of the Bcl-2 family proteins, 
caspase activation, and DNA fragmentation are the hallmarks (Gilmore et al, 2000). 
According to the present results of DNA-flow cytometry, apoptosis was detected in the 
MCF-7 cells, in terms of DNA fragmentation, after 48 h of incubation with CHL. Using 
bivariate JC-1 flow cytometry, it was further demonstrated in this study that there was 
mitochondrial membrane depolarization early at 24 h of treatment. It is well known that 
several stimuli induce a decrease in the mitochondrial membrane potential, which 
precedes nuclear fragmentation in apoptosis (Castedo et aL, 1996). Thus, these 
observations imply that apoptosis is involved in the cytotoxicity of CHL in the breast 
cancer cells. The Bcl-2 family proteins are the central regulators of apoptosis because 
they integrate diverse survival and death signals into membranes, especially 
mitochondrial outer membrane, that are generated outside and inside the cell (Strasser et 
al., 2000; Adams and Cory, 2001; Daniel et al, 2003). Immunoblot studies illustrated that 
the Bcl-2 expression was only reduced after 72 h of incubation with CHL while BC1-XL 
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and Bad expressions remained unchanged. Therefore, the Bcl-2 family proteins examined 
in this study were unlikely to cause the loss of mitochondrial membrane potential induced 
by the CHL treatment and the depletion of Bcl-2 expression might only participate in the 
exacerbation rather than the initiation phase of the cell death process. Bcl-2 family 
consists of three subfamily members, which are the Bcl-2, Bax and BH3-only subfamilies, 
with around 24 members in the mammalian cells (Daniel et al, 2003). Among them, 
Bcl-2, BCI-XL and Bad, which had been examined in this study, are some of the 
well-characterized candidates for their anti- or proapoptotic activity. Although Bcl-2 does 
not participate in the initiation phase of the cell death process, as well as BC1-XL and Bad, 
the possibility that those members of the Bcl-2 family, which had not been investigated in 
this study, might trigger the apoptosis could not be excluded. On the other hand, 
Halestrap et al. (2002) postulated that some agents can somehow oxidize the critical thiol 
groups in the mitochondrial membrane proteins to induce Bax/Bcl-2-independent 
mitochondrial membrane potential collapse and the release of apoptogenic molecules 
from mitochondria. Further studies are therefore needed to clarify whether this process, 
which is independent of the Bcl-2 family proteins, may indeed play an important role in 
the CHL-induced mitochondrial dysfunction leading ultimately to the cell death in the 
MCF-7 cells. 
Apoptosis induced by different stimuli, such as death ligands, chemotherapeutic 
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drugs, or ionizing irradiation, leads to the activation of caspases (Nicholson, 1999). The 
present investigation identified the cleavage of PARP starting from 24 h of incubation 
with CHL, which is an indication of caspase activation for cellular disassembly and 
serves as a marker of cells undergoing apoptosis (Kaufmann et al, 1993). Caspase-3 is an 
important effector caspase (Janicke et al” 1998; Porter and Janicke, 1999; Bratton et al., 
2000). It is interesting that, despite its lack in caspase-3 expression, MCF-7 still 
undergoes apoptosis induced by a host of exogenous stimuli, including vitamin D 
(Mathiasen et al.’ 1999), staurosporin (Janicke et al, 1998)，and neocarzinostatin (Schor 
et a l , 2000). Similarly, in this study, CHL induced apoptosis with caspase activations in 
the MCF-7 cells. Caspase-9 and -8 are the initiator caspases of the mitochondrial and 
death receptor apoptotic pathways respectively and caspase-6 and -7 are the effector 
caspases (Salvesen and Dixit, 1997; Thomberry and Lazebnik, 1998). The caspase 
activation involves cleavage of its procaspase. CHL did not affect the levels of 
procaspase-8 and -7，suggesting that the breast cancer cells were not killed via the death 
receptor pathway of apoptosis and caspase-7 did not take part in the execution phase of 
the cell death process. On the other hand, levels of procaspase-9 and -6 decreased after 
the CHL treatment, suggesting that the caspases might be cleaved and thus become 
activated during the cell death. This further suggested the involvement of the 
mitochondrial pathway in the CHL-induced apoptosis and caspase-6 as the effector 
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caspase. In addition, the abrogation of massive DNA fragmentation in the CHL-treated 
MCF-7 cells by the specific caspase-9 and -6 inhibitors further confirmed the 
involvement of these caspases in the cell death process. Diaz et al. (2003) reported that 
CHL induced apoptosis through activation of caspase-8 and caspase-6 in human colon 
cancer HCT116 cells. This observation suggested that CHL might trigger apoptosis via 
death receptor pathway in the colon cancer cells. Our findings, however, illustrated that 
mitochondria-dependent pathway took part in the CHL-induced apoptosis, leading to the 
activation of caspase-9 and -6 in the MCF-7 cells. The difference in the apoptotic 
mechanisms induced by CHL in the colon and breast cancer cells suggested that the 
anticancer effect of CHL might be specific to different cancer cell types. On the other 
hand, application of the general caspase inhibitor failed to completely retard the apoptosis 
in the CHL-treated MCF-7 cells, demonstrating a substantial contribution of some 
caspase-independent events in the cell death process. The discharge of apoptosis inducing 
factor (AIF) from mitochondria following loss of mitochondrial membrane potential 
mediates caspase-independent DNA fragmentation (Lorenzo et al, 1999). Diaz et al. 
(2003) also reported that CHL attenuated the mitochondrial membrane potential with the 
release of AIF and ultimately triggered apoptosis in human colon cancer HCT116 cells. 
The function of AIF in the CHL-induced apoptosis in the breast cancer cells needs further 
investigations. Nevertheless, the findings in this study revealed that caspase-8 and the 
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death receptor pathway do not participate but caspase-9 and the mitochondria-dependent 
pathway play actively in the activation of effector caspases, at least caspase-6, in the 
CHL-induced destruction of the breast cancer cells. Besides, the dying of the CHL-treated 
cells is determined not only by the caspase-mediated pathway but also via a coexisting 
caspase-independent route. 
One of the first studies to examine the inhibitory mechanisms of CHL on 
anticarcinogenic activity in vivo showed a decrease of cytochrome P450, an enzyme 
involved in bioactivation of several carcinogens, in liver microsomes of rats exposed to 
CHL by intraperitoneal (i.p.) injection (Imai et al,, 1986). Previous studies also illustrated 
that CHL inhibited carcinogenesis in trout and rat by intercepting and forming tight 
complexes with different mutagenic and genotoxic agents, and thereby diminishes their 
bioavailability by shuttling them through fecal stream (Dashwood, 1992; Breinholt et al” 
1999). Although CHL has been shown as anticarcinogenic agent in different animals, the 
direct in vivo effect of CHL on the growth of aberrant cells has never been investigated. 
In the present study, the in vivo efficacy of CHL as a potential anticancer agent was also 
determined in the MCF-7 solid tumor-bearing nude mice. CHL was found in this study to 
inhibit the tumor growth dose-dependently and deplete Cyclin Dl and Bcl-2 expressions 
in the tumor at the dose 50 mg/kg. Therefore, results of the in vivo studies correlate well 
with those of the in vitro studies that the CHL-induced growth inhibition of the MCF-7 
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cells is associated with the depletion of Cyclin Dl and Bcl-2 expressions. Interestingly, 
although 25 mg/kg CHL also significantly retarded the development of the breast cancer, 
no prominent changes of Cyclin Dl and Bcl-2 were observed at the dose. This implied 
that the in vivo application of CHL might trigger some anticancer mechanisms that have 
not been investigated in the present in vitro studies. Further studies are therefore required 
to study the pharmacokinetics and pharmacodynamics of CHL in the laboratory animals 
before the clinical trials on its anticancer activity in humans could begin. Nevertheless, 
results from the present studies provide novel insights into the in vivo anticancer 
mechanisms of CHL at least on the breast cancer MCF-7 cells. 
In conclusion, CHL was shown for the first time to inhibit the growth of the human 
breast carcinoma MCF-7 cells both in vitro and in vivo. The growth inhibition was 
mediated by both cell-cycle arrestment and apoptosis induction. As the cost of CHL is 
low and it is easily available and lacks of any known toxicity, the future development of 
CHL as a potent anticancer agent is valuable and deserved. 
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